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ABSTRACT 
 
Background: Mild cognitive impairment (MCI), a heterogeneous status, has gained increased interest 
from clinicians and researchers, because it has been shown to represent a transitional stage between 
normal ageing and very early Alzheimer’s disease (AD). Neuroimaging data, genetic findings, 
biological markers and neuropsychological tests have been evaluated as predictors of conversion from 
MCI into dementia, most commonly AD. Magnetic resonance imaging (MRI) using volumetric 
measurements of regions of interest (ROI), as well as more advanced imaging techniques, such as 
voxel based morphometry (VBM), increasingly used in studying AD patients, now were engaged in 
studying MCI subjects to determine which of them are to convert into dementia. Apolipoprotein E 
(APOE) allele ε4 is the most consistently confirmed genetic risk factor for Alzheimer’s disease (AD). 
Objectives: By using MRI volumetric studies to compare MCI subjects with controls and patients with 
mild AD, we intended to determine whether the entorhinal atrophy precedes hippocampal atrophy in 
AD. Moreover, with the help of VBM we wanted to map the gray matter loss in the entire brains of 
MCI subjects. As previous studies have suggested that the APOE genotype can influence the size of 
various brain structures, our objective was to investigate the difference in the morphologic expression 
of MCI in subjects carrying the APOE allele ε4 compared to the noncarriers using VBM. Finally we 
intended to conduct a follow-up study and determine the predictors for conversion into AD. 
Results: In the ROI-volumetric MRI study, we showed that the entorhinal volume loss predominated 
over the hippocampal volume loss in MCI, whereas more pronounced hippocampal volume loss 
appeared in mild AD. Using VBM in MCI subjects vs. controls, the greatest atrophy was found in the 
right hippocampus-amygdala region and in the right hippocampal tail and thalamus, while less 
extensive areas of atrophy were detected in the right superior temporal gyrus, the left thalamus, the left 
inferior temporal gyrus, and the left anterior cingulated gyrus. The extent of the atrophy was 
significant in the medial temporal lobe, on the right side. Between cases heterozygous for the APOE 
ε4 and those who were APOE ε4 noncarriers, only the right parahippocampal gyrus, with entorhinal 
cortex included, reached a level of statistical significance. In cases homozygous for the ε4 allele vs. 
noncarriers, the greatest atrophy was located in the right amygdala followed by the right 
parahippocampal gyrus, the left amygdala and the left medial dorsal thalamic nucleus. During the 
follow-up time of about 34 months, 21.7 % of the MCI subjects converted into dementia, with 15% 
developing AD. The right hippocampal and entorhinal volumes significantly predicted the conversion 
into AD. 
Conclusions: In the present study, the ERC atrophy appears to be dominant over the hippocampal 
atrophy in MCI, whereas more pronounced hippocampal atrophy was seen in mild AD. The VBM 
method revealed involvement of other brain areas, in addition to the MTL, in the state of MCI. The 
vast majority of the brain atrophy observed in individuals with MCI appears to be due to the small 
group homozygous for the ε4 allele. The atrophy of the MTL seen in the baseline, predicted the 
conversion to AD during a follow-up of 34 months, while the severity of cognitive impairment, the 
white matter lesions or the APOE provided no additional contribution to the prediction of conversion 
of MCI to AD. 
 
National Library of Medicine Classification: QU 470, QZ 180, WL 141, WL 314, WM 220, WN 185, 
WT 155 
Medical Subject Headings: Alleles; Alzheimer Disease/physiopathology; Amygdala/pathology; 
Apolipoproteins E/genetics; Atrophy; Brain/pathology; Cognition Disorders/genetics; Dementia/ 
physiopathology; Entorhinal Cortex; Hippocampus/physiopathology; Magnetic Resonance 
Imaging/methods 
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1. INTRODUCTION 
 
Dementia is a major cause of disability in the developed countries and places a considerable 
financial burden on the medical services and health care systems (Erkinjuntti et al., 1986; Hay 
and Ernst, 1987). An important public health concern of developed countries is aging of the 
population and the associated increases in the prevalence of various dementias, particularly 
Alzheimer’s disease (AD). The concept of mild cognitive impairment (MCI) refers to a 
transitional stage between normal ageing and very early AD. MCI, a heterogeneous entity, has 
been associated with a 10-fold risk for developing dementia, most commonly AD (Petersen et 
al., 2001 a). AD is one of the most important causes of dementia, and one of the most 
important reasons for the need for long-term patient care. Therefore, an increasing interest has 
been focussed on MCI in research into aging-related cognitive disorders, particularly in 
identifying early AD both for research purposes and as a way to achieve early therapeutic 
intervention. An annual conversion rate of 6-25% from MCI to AD has been reported, which 
greatly exceeds that seen in the normal population (1-2%) (Petersen et al., 2001 a). 
Nevertheless, the epidemiology of MCI is not well known, and some longitudinal population 
based studies have cast some doubt on the concept of MCI. In the study by Larrieu et al., an 
annual conversion rate of 8.3% was observed during a five-year period, but again the cases 
had a tendency to fluctuate, and as many as 40% of MCI cases reverted to normal instead of 
progressing to dementia during follow up (Larrieu et al., 2002). 
 
Subjects with MCI are characterised by memory complaints, normal general cognitive 
functions, impaired memory for age, preserved activities of daily living, and they are not 
demented, but the criteria used for diagnosing MCI have varied in different studies. For this 
reason, new recommendations for the general criteria for MCI, as published by the Stockholm 
consensus group, suggesting that the MCI construct should be expanded to include cognitive 
impairment in other domains such as language, attention, visuospatial skills, perceptual speed, 
and executive function (Winbland et al., 2004). Several approaches have been attempted to 
identify among MCI subjects, those who will progress to dementia and AD. The 
heterogeneity in the use of term has been recognised and independently from the criteria used 
to diagnose the MCI, predicting factors to AD, such as neuroimaging data, genetic findings, 
biological markers, and neuropsychological tests have been suggested. For that purpose 
magnetic resonance imaging (MRI) using volumetric measurements of regions-of-interest 
(ROI) have been used in many studies. It was shown that the neuropathological changes 
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occurring in AD develop gradually, first appearing in the entorhinal cortex (ERC) and later 
progressing to the isocortical areas. Accordingly, studies in vivo on brains such as volumetric 
MRI indicated that atrophy of the hippocampus and the ERC could be a sensitive indicator of 
early AD (Jack et al., 1999; Killiany et al., 2002). Moreover, atrophy of the ERC has been 
suggested to predict AD during its preclinical stage (Killiany et al., 2002). While volumetric 
studies focus on selected ROIs, voxel-based morphometry (VBM) is able to map the entire 
brain and to provide a global picture of the studied group of subjects with high reproducibility 
(Ashburner et al., 2003). Apolipoprotein E (APOE) ε4 allele is the most consistently 
confirmed genetic risk factor for AD. The APOE ε4 has been associated with the development 
of AD among individuals with MCI (Petersen et al., 1995) and it is also associated to 
amnestic-MCI (Lopez et al., 2003). The ε4 carriers show an earlier age of onset and enhanced 
AD related pathology compared to non-carriers (see for review Lehtovirta et al., 2000) and 
more pronounced atrophy in the medial temporal lobe (MTL) structures (Juottonen et al., 
1998 a; Geroldi et al., 1999; Geroldi et al., 2000). Finally, to conclude what are the 
neuropsychological, brain imaging and genetic factors that better predict the conversion of 
MCI subjects to dementia, especially to AD, we need to conduct follow-up studies of MCI 
subjects. 
 
In this study, brain atrophy was examined using two different imaging methods for volumetric 
measurements in a preclinical stage of AD so called MCI, and the predicting value of the 
MTL atrophy for developing AD, together with other features characteristic for AD were 
examined in MCI subjects. 
17 
2. REVIEW OF THE LITERATURE 
 
2.1. Aging, Dementia and AD 
 
2.1.1. Aging 
 
Successful aging can be accounted for surviving and functioning. A decline in cognitive 
functioning that affects on the daily life will conduct towards dementia. Therefore, bringing 
up the subject of AD, dementia or mild cognitive impairment, one would first stop on the 
condition of aging, with different descriptions: usual, normal, and successful (Rowe and 
Kahn, 1987). Unfortunately, forgetfulness is present to some degree, from time to time in 
almost all of us. Memory function as measured by delayed recall of newly learned material is 
not clearly impaired in most elderly individuals (Geffen et al., 1990; Mitrushina et al., 1991; 
Petersen et al., 1992; Knopman et al., 2003). Nonetheless, variability has been proposed to be 
increased with age, and life style and psychosocial factors to have influence on the 
heterogeneity of the older population and their aging process (Rowe and Kahn, 1987). While 
normal aging can be associated with a deterioration in different aspects of cognitive 
performance, the progression of mentioned phenomena could transform normal aging into 
dementia. 
 
2.1.2. Definition of dementia 
 
Dementia is a major public health problem, with no mercie for gender or for different ethnic 
and socioeconomic groups. Just as fever is attributed to many etiologies, dementia is a non-
specific term that encompasses many disease entities. The word dementia is derived from 
latin de- "apart, away” and mens - on genetive, mentis "mind", so de mens - "without mind" 
and it is used scientifically for describing a progressive decline in cognitive function due to 
damage or disease in the brain, beyond what might be expected from normal aging. The term 
cognition comes from Latin as cogito, "to think" and it is used in several loosely-related ways 
to refer to a facility for the intelligent processing of information. In other words, dementia is a 
syndrome of brain dysfunction, with symptoms dependent upon the etiology of the disease. 
The affected areas may be memory, attention, language and problem solving, although 
particularly in the later stages of the condition, affected persons may be disoriented in time, 
place and identity. 
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There are different sets of criteria available for the diagnosis of dementia, as many authors 
and associations have tried to define it (American Psychiatric Association 1980 (DSM-III), 
1987 (DSM-III-R) and 1994 (DSM-IV); Small et al., 1982; Cummings and Berson, 1983; 
McKhann et al., 1984; Dementia. Council on Scientific Affairs, 1986). The Diagnostic and 
Statistical Manual of Mental Disorders (DSM) of the American Psychiatric Association 
provides the most frequently used definition of dementia in the version III (DSM-III) 
(American Psychiatric Association, 1980), in the revised third version (DSM-III-R) 
(American Psychiatric Association, 1987), and in the version IV (DSM-IV) (American 
Psychiatric Association, 1994). The DSM-IV defines dementia as "the development of 
multiple cognitive deficits that include memory impairment and at least one of the following: 
aphasia, apraxia, agnosia, or a disturbance in executive functioning" (American Psychiatric 
Association, 1994.). The executive functioning is seen as the ability to inhibit inappropriate 
answers and to select behaviors for action. Thus, the memory impairment is necessary for 
defining this condition and the disturbances should interfere with the daily life. The cognitive 
impairment must be more pronounced than encountered in normal aging. 
 
2.1.3. Alois Alzheimer and Alzheimer's disease 
 
In medicine, eponymy has been traditionally used to memorialize the first diagnostician of a 
syndrome or a disease. That happened also with AD. Alois Alzheimer was born in June 14, 
1864 in Marktbreit near Wurzburg in Franconia, Germany. In 1888 he obtained his first post 
at the Mental Asylum, Irrenanstalt, in Frankfurt am Main, where later, the 51-year-old patient, 
Frau Auguste D was admitted, on November 25, 1901 and died on April 8, 1906. Alzheimer 
described her case of presenile dementia at the meeting of South-West Germany Psychiatrists 
in Tubingen, 1906 and published his presentation in 1907 (Alzheimer, 1907). While in life, 
the patient had shown a progressive decline in cognitive function, disorientation, aphasia, 
delusions, and psychosocial incompetence, at autopsy there were plaques and neurofibrillary 
tangles (NFT) and arteriosclerotic changes (Maurer et al., 1997). This was the original AD 
patient. As Bick KL remarked in the detailed historical description of Alzheimer’s disease 
(Terry et al., 1999), “Alzheimer did not bestow his name on the condition he described”, in 
fact Emil Kraepelin was the individual who introduced this disease as Alzheimer's disease in 
the category of presenile dementias in the 1910 edition of his textbook (Kraepelin, 1910). On 
the other hand, Alzheimer did not object to Kraepelin's designation, as he refers to it in his 
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publication (Alzheimer, 1911 - English translation in Förstl and Levy, 1991) on the report of 
a second patient with Alzheimer's disease, the case of 56-year-old male, Johann F. He states 
that Kraepelin has already given a summarized account on this disease and called it 
"Alzheimer's disease" (Möller and Graeber, 1998). 
 
2.1.4. Diagnosis of AD 
 
2.1.4.1. Clinically 
 
Dementia has attracted extreme interest from public, clinicians and researchers, as the world 
population is aging. A major cause of dementia has been proposed to be AD, a progressive 
neurodegenerative disease, with a gradual onset varying between 40 and 90 of age and with a 
life span varying between 5 to 15 years after onset. The National Institute of Neurological and 
Communicative Disorders and Stroke and Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA) (McKhann et al., 1984) presented the most widely used 
criteria for clinical diagnosis of AD (Table1). The NINCDS-ADRDA criteria for clinical 
diagnosis of probable AD are equivalent with the criteria for defining the dementia of the 
Alzheimer type (DSM-IV) (American Psychiatric Association, 1994). Early diagnosis of AD 
is mainly based on clinical, neuropsychological, and brain imaging findings and exclusion of 
other possible causes for dementia, but no definite early tool for diagnosing the disease in 
point has been found until today. According to the NINCDS-ADRDA criteria, AD is divided 
into three categories: possible, probable and definite AD. The diagnosis of definite AD can be 
confirmed only by histopathological examination of the brain tissue obtained either by biopsy 
or at autopsy. Before that, a diagnosis of probable or possible AD has to be accepted (Table 
1). Shortly, patients with probable AD are characterized by gradual onset and progression of 
memory and cognitive decline, and do not present any signs of other disorders that could 
cause dementia. The diagnosis of  AD is supported by: progressive deterioration of specific 
cognitive functions such as language (aphasia), motor skills (apraxia), and perception 
(agnosia); impaired activities of daily living and altered patterns of behavior; family history of 
similar disorder, particularly if confirmed neuropathologically; normal cerebrospinal fluid 
(CSF) samples as evaluated by standard techniques; normal pattern or nonspecific changes in 
electroencephalography (EEG); and evidence of cerebral atrophy on brain imaging with 
progression documented by serial observation. 
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Table 1. The criteria for diagnosing AD according to the National Institute of Neurological 
and Communicative Disorders and Stroke and Alzheimer ’s disease and Related Disorders 
Association (NINCDS-ADRDA) 
 
Criteria for clinical diagnosis of PROBABLE Alzheimer's disease: 
-dementia established by clinical examination and documented by objective testing; 
-deficits in two or more areas of cognition; 
-progressive worsening of memory and other cognitive functions; 
-no disturbance of consciousness; 
-onset between ages 40 and 90; 
-absence of systemic disorders or other brain diseases that in and of themselves could account 
for the progressive deficits in memory and cognition. 
Criteria for clinical diagnosis of POSSIBLE Alzheimer's disease: 
-may be made on the basis of the dementia syndrome, in the absence of other neurologic, 
psychiatric, or system disorders sufficient to cause dementia, and in the presence of variations 
in the onset, in the presentation, or in the clinical course; 
-may be made in the presence of a second systemic or brain disorder sufficient to produce 
dementia, which is not considered to be the cause of dementia; 
-should be used in research studies when a single, gradually progressive severe cognitive 
deficit is identified in the absence of other identifiable cause. 
Criteria for diagnosis of DEFINITE Alzheimer's disease are: 
-the clinical criteria for probable Alzheimer's disease; 
-histopathologic evidence obtained by biopsy or autopsy. 
 
 
 
2.1.4.2. Neuropathologically 
 
The neuropathological hallmarks of AD are amyloid plaques and neurofibrillary tangles 
(NFT) (Khachaturian, 1985; Braak and Braak, 1991 b; Mirra et al., 1991), but also other 
important signs are present: neuronal loss (Gomez-Isla et al., 1997) and synaptic loss (Hamos 
et al., 1989). The one neuropathological abnormality required for the definite diagnosis of AD 
is an adequate number of extracellular amyloid plaques (Khachaturian, 1985). This is 
according to the currently used neuropathological diagnostic criteria for AD, the 
Neuropathology Task Force of the Consortium to Establish a Registry for Alzheimer’s 
Disease (CERAD) (Mirra et al., 1991), a hallmark feature of the disease. The second 
neuropathological hallmark is the presence of neurofibrillary tangles (NFT) found inside the 
neurons, which form the basis of the Braak&Braak criteria with topographical staging (Braak 
and Braak, 1991 a; Braak and Braak, 1995). Accordingly, six stages of disease propagation 
can be distinguished with respect to the location of the NFTs: “transentorhinal stages I-II: 
clinically silent cases; limbic stages III-IV: incipient Alzheimer's disease; neocortical stages 
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V-VI: fully developed Alzheimer's disease” (Braak and Braak, 1995). Recently, a new set of 
criteria - based on both guidelines of CERAD and Braak&Braak criteria – was proposed by 
the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria 
for the neuropathological assessment of Alzheimer’s disease (NIA) (NIA, 1997). The fact is 
that there are aged people free of any symptoms, and nevertheless on autopsy they present the 
neuropathological changes characteristic of AD. It was concluded in a recent review that 
disease-related pathological changes are the signs for an incipient disease like AD, rather than 
the effects of aging, even though there is a lack of clinical symptoms (Thal et al., 2004). 
 
2.2. MCI 
 
2.2.1. The concept of MCI 
 
MCI is currently the most widely used concept in classifying cognitive impairment in the 
elderly who do not fulfil the criteria for dementia. Up to the present, a great interest was given 
to the changes responsible for cognitive impairment that are providing towards dementia, or 
to AD. For that, the boundary between normal aging and early AD has become the area of 
major interest for researchers and clinicians for theoretical and practical reasons (Petersen et 
al., 2001 a). Over the years, different concepts have been used to identify an intermediate 
stage of cognitive changes, for example: Benign senescent forgetfulness (Kral, 1962), Age-
associated memory impairment  (AAMI) (Crook et al., 1986), Age-associated cognitive 
decline (AACD) (Levy, 1994), Age-related cognitive decline (DSM-IV) (American 
Psychiatric Association, 1994), Mild cognitive disorder (ICD 10), Cognitive impairment - no 
dementia (Graham et al., 1997), Mild Cognitive Impairment (MCI) (Smith et al., 1996; 
Petersen et al., 1999). The concept of MCI has been the most recent research topic with still 
open questions on a large spectrum of issues involved in it (Petersen, 2003). 
 
It should be noted that mildly impaired non-demented subjects form a heterogeneous group 
that includes stable subjects and subjects who will develop AD (Petersen, et al., 1995; 
Petersen, et al., 1999; Petersen et al., 2001 a), but also subjects that revert to normal aging 
(Larrieu et al., 2002). The heterogeneity (Figure 1) of the MCI group consisting of subjects 
declining to non-AD dementia, those progressing to AD, those that are stable and those that 
will revert to normal aging, may be viewed from two perspectives (Petersen, 2003): 
etiological or clinical presentation (Petersen et al., 1999). The most of decliners to AD are 
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those from the amnestic-MCI group of subjects, and they are characterized by impairment of 
the memory to 1.5 SD below age- and education matched normal subjects (Petersen et al., 
1999). The memory impairment is a clinical judgment based on the subject’s history, on the 
clinician’s examination and on the neuropsychological profile, and it represents the main 
feature in the definition of MCI. Subsequently, memory impairment will remain the most 
important feature in diagnosing dementia, while other cognitive disturbances will interfere 
with the daily life (DSM-IV) (American Psychiatric Association, 1994). 
 
In the Mayo Clinic, a progression rate of almost 12% per year was seen in declining from 
MCI to dementia or to probable AD, while the control cohort declined to MCI or to AD with 
a rate of only 2% per year (Petersen et al., 1999). The Report of the Quality Standards 
Subcommittee of the American Academy of Neurology reviewed in 2001 a number of studies 
and, even though these studies had used various criteria for MCI, they indicated an annual 
conversion rate of 6%–25% from MCI to AD (Petersen et al., 2001 a). Thus, investigating 
MCI might provide a means to study AD in its earliest phases and this might prove beneficial 
in terms of finding preventive or interventive measures for AD. However, some recent 
longitudinal population based studies have cast some doubt on the concept of MCI. Ritchie 
and colleagues suggested that MCI is a poor predictor of dementia, that the group is unstable, 
with cases changing category almost yearly, and they called for modifications to the current 
criteria (Ritchie et al., 2001). In the study by Larrieu et al. (2000), an annual conversion rate 
of 8.3% was observed during a five-year period, but again the cases had a tendency to 
fluctuate, and as many as 40% of MCI cases reverted to normal instead of progressing to 
dementia during the follow up. When considering the new recommendations for MCI criteria 
(Winbland et al., 2004), Alexopoulus and colleagues (2006 a) found that 17% of the MCI 
subjects returned to normal over a mean follow-up period of time of 3.5 years. The multiple-
domain type of MCI had a less favorable prognosis than the amnestic type in progressing to 
dementia (p<0.014) (Alexopoulos et al., 2006 b). Contrary, Yaffe and colleagues (2006) 
found that nonmemory and multiple-domain MCI subjects were less likely to progress to 
dementia than amnestic MCI subjects were, while among those that converted to AD, most 
had prior amnestic MCI. 
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Figure 1. The meaning of heterogeneity in MCI subjects. Both, the etiology of MCI and the 
clinical presentation will affect the heterogeneity of MCI group of subjects (adapted from the 
book edited by Petersen RC, 2003). Accordingly, MCI subjects will revert to normal, remain 
stable, or progress to AD or other dementias with time. The clinical presentation after 
Petersen et al.: Amnestic MCI – memory impaired to 1.5 SD below age- and education- 
matched normal subjects, while other domains are impaired to 0.5 SD; Multiple-domain MCI 
– several cognitive domains impaired to 0.5 SD below age- and education- matched normal 
subjects; Single non-memory-domain MCI – impairment is seen in other cognitive functions, 
for example in: executive function, visuospatial function, language. 
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In different studies, different criteria for defining MCI subjects have been used and the source 
of study differs, yielding different results. In some studies, the subjects are those who have 
actually sought an evaluation from a dementia clinic for different symptoms, and in others, 
they derive from community-based settings. Thus, differences exist in study designs, and 
ultimately the investigators need to interpret the results according to the limitations of their 
own study settings. Many ongoing studies continue to concentrate on MCI as a transitional 
stage between normal aging and AD or dementia. 
 
2.2.2. Diagnosis of MCI 
 
The criteria for MCI have been refined with time, but those used by many studies, including 
the current work, were based on the adaptation of the criteria suggested by Mayo Clinic 
Alzheimer's Disease Research Center (MCADRC) (Petersen et al., 1995; Smith et al., 1996): 
1) memory complaint by patient, family or physician;  
2) normal activities of daily living;  
3) normal global cognitive function;  
4) objective memory impairment or impairment in one other area of cognitive function as 
evidenced by scores >1.5 SD below age apropiate mean;  
5) Clinical Dementia Rating score of 0.5; and  
6) not demented.  
 
Later those criteria were modified (Petersen et al., 1999):  
1) memory complaint;  
2) normal activities of daily living; 
3) normal general cognitive function; 
4) abnormal memory for age; 
5) not demented. 
 
A group of experts in aging and MCI (Petersen et al., 2001 b) and the subcommittee of the 
American Academy of Neurology (Petersen et al., 2001 a) have summarised the criteria for 
MCI, and placing the emphasis on the heterogeneity of this group of subjects, they defined 3 
subgroups (Petersen et al., 2001 b): amnestic-, multiple domains slightly impaired- and single 
nonmemory domain MCI. Thus, MCI criteria became: 
1) memory complaint, preferably corroborated by an informant 
2) objective memory impairment 
3) normal general cognitive function 
4) intact activities of daily living 
5) not demented. 
 
Moreover, the amnestic MCI, considered as being the precursor for AD, is defined as: 
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1) memory complaint, preferably corroborated by an informant 
2) impaired memory function for age and education 
3) preserved general cognitive function 
4) intact activities of daily living 
5) not demented. 
 
In 2003 during the First Key Symposium in Sweden, on the topic of MCI, an international 
multidisciplinary group of experts discussed the current status and new perspectives on 
clinical, cognitive neuroimaging, biomarkers and genetics fields in MCI. They gave 
recommendations for the general criteria for MCI, and published them in 2004 (Winblad et 
al., 2004): 
1) Not normal, not demented (does not meet the DSM-IV, ICD 10 criteria for a dementia 
syndrome) 
2) Cognitive decline: 
- self and /or informant report and impairment on objective cognitive tasks 
and/or 
-evidence of decline over time on objective cognitive tasks 
3) Preserved basic activities of daily living/minimal impairment in complex instrumental 
functions. 
 
This new set of criteria allows inclusion of deficits in cognitive domains other than memory, 
while the amnestic MCI would be then left as the precursor for AD, rather than for other 
dementias. Still, the clinical criteria as proposed by Petersen and colleagues, have varied from 
one study to another. Nevertheless, the criticisms raised against MCI criteria have not 
disappeared, and perhaps the criteria will be modified in the future. Recently, during a session 
of the MCI working group from the European Alzheimer's Disease Consortium (EADC), in 
2005 a new set of criteria were presented for review (Portet et al., 2006): 
1) cognitive complaint emanating from the patient and/or his/her family 
2) the subject and/or informant report a decline in cognitive functioning relative to previous 
abilities during the past year 
3) cognitive disorders evidenced by clinical evaluation: impairment in memory and/or another 
cognitive domain 
4) cognitive impairment does not have major repercussions on daily life. However, the subject 
may report difficulties concerning complex day-to-day activities, 
5) no dementia. 
 
However, based on this report of the EADC, Portet and colleagues considered that in addition 
to those proposed criteria that would identify patients at risk to develop dementia, some more 
elaborate tests, like for example neuroimaging, will be still needed to determine the 
underlying cause of a diagnosed MCI state (Portet et al., 2006). 
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2.3. Imaging as an in vivo tool to study the brain 
 
In studying the normal state of human brain and diagnosing cognitive pathology, MRI gained 
an important role as it provides qualitative and quantitative in vivo insights into brain 
morphology. New techniques are being developed continuously, and neuroimaging has 
become part of the diagnostic process of persons suspected for dementia. Quantitative 
structural studies are conducted both cross-sectionally and longitudinally and consist of 
volumetric measurements that focus on selected ROI, and computational methods that give 
insights into the global morphological changes in brain. 
 
The goal for imaging studies is to achieve a consensus on applying imaging methods for early 
and differential correct diagnosis in dementia as a routine clinical procedure, as well as for 
monitoring the progress and outcome in drug trials. For that rationale, a "combination of a 
distinctive biochemical profile with quantitative neuroimaging, used in conjunction with 
clinical and neurobehavioral assessment" is urgently needed, as remarked by Black (1999) in 
what concerns the diagnosis of AD. According to the practice parameter on dementia 
(Knopman et al., 2001) the neuroimaging with MRI or computed tomographic (CT) plays a 
key role in the initial evaluation of a demented patient, as a means of ruling out structural 
lesions such as brain tumors, abcesses, strokes and hematomas. For this reason, the practice 
parameter supported the use of MRI or CT at the time of the initial dementia assessment. The 
Consensus Report of the Alzheimer's Association Neuroimaging Work Group recommended 
an extension of the guidelines of the American Academy of Neurology to include brain 
imaging as a part of the dementia evaluation in subjects when not only AD is suspected but 
also including amnestic MCI subjects (Neuroimaging Work Group, Alzheimer's Association. 
Consensus Report, 2004). The Work Group has recommended standardised analyses on the 
structural MRI, including the brain measurements of global loss and MTL volume, with the 
accent on longitudinal structural MRI study on brain atrophy rates that would provide 
information useful for the design of treatment studies (Neuroimaging Work Group, 
Alzheimer's Association. Consensus Report, 2004). 
 
In what concerns the clinical practice, the visual rating method has high potential to be used 
in the clinical routine procedure for dementia investigations in the future. The visual rating 
method developed by Scheltens et al. (1992, 1995) has been applied to determine its value in 
differentiating AD patients from controls based on the MTL evaluation and has been 
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compared to that of a stereological volumetry method, a simplified version of manual tracing 
(Wahlund et al., 1999; Wahlund et al., 2000). 
 
As for monitoring treatment effect in drug trials in AD promising results have been obtained 
by the boundary shift integral (BSI) method, an algorithm developed by Fox and colleagues 
(1996) and tested for brain (BBSI)-derived changes registered from serial MRI (Freeborough 
and Fox, 1997 and Fox and Freeborough, 1997). The BSI technique has been recently tested 
also for ventricular (VBSI)-changes and compared to BBSI changes in trials of a follow-up of 
6 months and 1 year (Schott et al., 2005). 
 
The BBSI and VBSI rates of change have been also compared to the ROI-based methods for 
ERC and hippocampus atrophy rates in classifying AD patients and controls (Ezekiel et al., 
2004). While the rates of change were VBSI > ERC & hippocampus > BBSI in both groups, 
the combined rates of ERC and VBSI were the best explanatory variables for differentiation 
between the two groups of subjects. However, this study suggested that ERC and 
hippocampal atrophy rates might be more sensitive than BBSI or VBSI in monitoring the AD 
progression and the potential effects of disease modifying agents. 
 
The neuroimaging methods and their efficacy differ according to the intention of use, such as 
clinical or research imaging tool, and the characteristics of those instruments with potential 
use in different clinical settings, are found in the consensus paper produced by the 
Neuroimaging Working Group of the European Alzheimer's Disease Consortium (EADC) 
(Frisoni et al., 2003). 
 
The present work focuses on the most widely used neuroimaging tools for assessing the brain 
morphology, the manual tracing ROI-based MRI volumetry and the voxel-by-voxel method. 
 
2.3.1. Imaging in normal aging brain - a view towards AD 
 
2.3.1.1. Structural MRI and gray matter 
 
Before one can define the abnormal there has to be a guideline for what is normal. Therefore, 
the imaging of the normal aging brain is an important issue, both for an in vivo regular 
anatomical presentation of the brain, and for the changes that are related to it. 
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Neuropathological studies have revealed changes in brain with advancing age. There is a 
constant hemisphere volume in individuals between the ages of 20 and 50 years (Miller et al., 
1980), but thereafter there is a decrease in volume of 2% per decade (Miller et al., 1980; 
Jernigan et al., 1990).  
 
Thus, after age of 50, the brain size suffers atrophy increased with age, but different studies 
have reported changes in brain connected with the process of maturisation of brain during its 
life span: both global and selective decreases in cortical volume and an increase in ventricular 
volume have been detected in MRI studies. While Coffey and colleagues detected an age-
associated decline in the volume of cerebrum both gray and white matter included (Coffey et 
al., 1992), Pfefferbaum and colleagues measured only the volume of cortical gray matter and 
found as well a linear decrease associated with age (Pfefferbaum et al., 1994). Different brain 
structures are involved in the process of age-related shrinkage and this is not uniformly 
distributed in the brain (Raz et al., 1997). Age related changes have been described in 
posterior frontal lobe with a decrease of about 1% per year, but not in temporal lobe in a 
group of subjects aged from 19-92 (DeCarli et al., 1994). Accordingly, Coffey and colleagues 
found in 76 subjects aged 30 to 90 years a frontal lobe volume reduction of 0.55% per year, 
but they also described a small decrease in temporal lobe (0.28% per year) (Coffey et al., 
1992). 
 
Regional brain volumes, such as those of hippocampus, parahippocampal gyrus and amygdala 
declined with increasing age according to some studies (Jack et al., 1997; Convit et al., 1995), 
while other studies detected no age effect on the hippocampal volume (Sullivan et al., 1995; 
Jack et al., 1989) or a very weak age effect (Raz et al., 1997). The "negative" results were 
obtained in studies including younger subjects, aged 21 to 70 years (Sullivan et al., 1995), or 
even 20 to 40 years (Jack et al., 1989). Thus, the results on age effect are somewhat 
contradictory but much of the variation is due to the different protocols used in choosing the 
study subjects as concerns age and number, or in measuring brain structures. For this same 
reason some workers have found a decline associated with age in hippocampal volume, but 
not in temporal lobe or the whole-brain (a study on 29 young adults) (Bhatia et al., 1993), 
while others found by contrast that left and right temporal lobe gray matter volumes, 
exclusive of the hippocampal measures, each decreased significantly with age (a study on 72 
subjects aged 21 to 70 years) (Sullivan et al., 1995). 
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Brain changes rely mostly on cross-sectional studies. However, a better perspective on what 
may be the effect of age on brain's volume should be given by longitudinal studies. In a five-
year study, Raz and colleagues reported an age-related shrinkage in the medial temporal lobe 
with a significant hippocampal decline, but minimal entorhinal changes (Raz et al., 2004). 
Later the longitudinal study by Raz and colleagues did detect age related shrinkage of the 
hippocampus and ERC, but accelerated shrinkage only in the hippocampus (Raz et al., 2005). 
These results are of particular importance when studying changes in brain related to dementia 
or AD. 
 
2.3.1.2. A view towards AD 
 
There is evidence that, although the hippocampus is affected early in the course of AD, the 
ERC is the first region to exhibit AD-type pathology (Van Hoesen and Hyman, 1990; Van 
Hoesen et al., 1991; Braak and Braak, 1991 a; Arriagada et al., 1992; Huesgen et al., 1993; 
Gomez-Isla et al., 1996). While in cognitively normal subjects (Clinical Dementia Rating 
(CDR) Scale = 0) the number of neurons in the ERC has remained constant between 60 and 
90 years of age, even in the mildest form of dementia (CDR = 0.5) the number of neurons 
decreased by 32% (Gomez-Isla et al., 1996). Neurodegenerative changes in AD are 
accompanied by brain atrophy with changes generally seen in both gray and white matter 
(Mann, 1991). In layer II of the ERC, neuronal loss together with atrophy exists prior to the 
onset of dementia and is correlated with MMSE (Kordower et al., 2001), and hippocampal 
volumetry has been shown to correlate with neuronal (Bobinski et al., 2000) and tangle counts 
(Huesgen et al., 1993). Moreover, while MMSE and Braak&Braak stage are correlated, 
hippocampal volume measured on MRI scans correlates with each of them (Jack et al., 2002). 
 
2.3.1.3. Structural MRI and white matter 
 
Age-related white matter changes have been reported in some studies to appear between 30 to 
79 years (Jernigan et al., 1991). Other studies reported that until 20 years of age, the cortical 
white matter volume increased steadily (subjects aged 3 months to 30 years), while after that 
age it remained constant (subjects aged 21 to 70 years) (Pfefferbaum et al., 1994). Coffey and 
colleagues reported a 6.3% per year increase in subcortical hyperintensity in the deep white 
matter in a sample of young healthy adults (Coffey et al., 1992). Age-related changes in white 
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matter have been presented also by Raz and colleagues, with no or very weak association with 
age (Raz et al., 1997). 
 
2.3.1.4. VBM - gray and white matter 
 
Apart of structural studies that concentrate on specific brain regions, of great importance are 
also other quantitative MR techniques that measure functional, blood-flow, biochemical or 
global anatomic changes occurring in the brain (Kantarci and Jack, 2004). One such approach 
is the voxel-based morphometric (VBM) method for studying the brain, which allows 
measurements of whole brain instead of a specific brain region. The voxel-by-voxel 
measurements indicate that prefrontal cortex and MTL are relevant structures both in aging 
and age-related cognitive decline in healthy elderly subjects (Tisserand et al., 2004). In the 
study by Good et al. (2001 a), a total of 465 normal adults were examined for age effects on 
gray and white matter. Accelerated volume loss with increasing age was seen in the insula, 
superior parietal gyri, central sulci and cingulate sulci, while little or no age effect was seen in 
the amygdala, hippocampus and ERC. Generally, a linear decline in gray matter was seen in 
normal aging, with sparing of the temporal lobe. White matter was in global terms not 
affected by age; nevertheless, local areas with age-related changes were seen. 
 
2.3.2. Imaging in AD 
 
Quantitative MRI measurements have been used to assess the volumetric AD changes in well-
defined brain regions, selected according to the pathological changes known to occur in AD 
(Van Hoesen et al. 1991; Braak and Braak, 1991 a; Arriagada PV et al., 1992; Huesgen et al., 
1993; Gomez-Isla et al., 1996). Neuroimaging, otherwise a part of the diagnostic workup of 
persons suspected for dementia, is even thought to be superior to the neuropsychological tests 
for early diagnosis of AD (Zamrini et al., 2004). A backup for studying certain ROIs are the 
reports of evidence that even cognitive intact subjects or MCI subjects can carry a burden of 
AD pathology (Huesgen et al., 1993; Bobinski et al., 2000; Jack et al., 2002). The MTL 
became therefore, an attractive target for MRI measurements. Structural brain studies are 
assessed with both ROI based measurements and global, computational based measurements, 
such as the VBM approach. In ROI measurements, the most consistent finding in AD has 
been hippocampal atrophy accompanied by ERC atrophy, and in general an atrophy of the 
MTL (see for review Dickerson and Sperling, 2005; Masdeu et al., 2005). Compared to 
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controls, the annual rate of hippocampal volume loss is two to three times greater in mild AD 
patients, ranging from 4-8% per year (Laakso et al., 2000; Jack et al., 2000). In cross-
sectional studies, volume losses of 38% for the hippocampus (Laakso MP et al., 1995) and 
40% for the ERC (Juottonen K et al., 1998 b) were registered in patients with mild to 
moderate AD versus controls. Accordingly, compared to MCI subjects, a volume loss of 19% 
for the hippocampus and 30% for the ERC has been reported (Du et al., 2001). While 
structures of the MTL, especially hippocampus and ERC, are considered MRI markers for 
AD, there are volumetric studies, which have focussed on other than temporal regions. Callen 
and colleagues studied the limbic system throughly: hippocampus, amygdala, 
parahippocampal cortex and "beyond the hippocampus", the anterior thalamus, hypothalamus, 
mamillary bodies, basal forebrain, septal area, fornix, and cingulate and orbitofrontal cortices 
(Callen et al., 2001). All the limbic structures exhibited significant atrophy, with the 
exception of one region: the anterior cingulate cortex. 
 
The volumetric measurements were also studied from the discriminant point of view, since 
this has implications for the early diagnosis of AD (see for review Chetelat and Baron, 2003). 
Reviewing a good set of cross-sectional case-control studies, in 2004 Kantarci and Jack 
remarked that "the entorhinal cortex and hippocampus volumes are generally considered to be 
the most accurate in differentiating patients clinically diagnosed with AD from normal" 
(Kantarci and Jack, 2004). A combined atrophy of the limbic structures was used to 
distinguish patients with AD from controls with over 90% accuracy (Callen et al., 2001). 
Lehericy and colleagues (1994) achieved 100% accuracy in discriminating AD patients from 
controls combining the volume of hippocampus with that of amygdala; nonetheless, with 
hippocampus alone the accuracy achieved was only 89% (Lehericy et al., 1994). In addition, 
100% accuracy in distinguishing mild AD patients from controls was achieved by combining 
partial ERC volume (measured from 3 slices) with measurements of the banks of the superior 
temporal and anterior cingulate sulci (Killiany et al., 2000). While some investigators have 
found almost no differences in the power of hippocampus and that of ERC for discrimination 
between AD patients and controls (Juottonen et al., 1999; Du et al., 2001), some others have 
reported a lower accuracy for the ERC (67%) than for the hippocampus (85%) for the same 
purpose (Frisoni et al., 1999). 
 
More recent studies have paid attention on computational methods for analysing the atrophy 
throughout the brain, and in general if, focusing on VBM studies, they have confirmed 
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previous ROI-based findings that the brain atrophy is concentrated in the temporal lobe in AD 
(Ohnishi et al., 2001; Frisoni et al., 2002; Busatto et al., 2003). Yet, some investigators have 
found a widespread distribution of the atrophy (Baron et al., 2001; Karas et al., 2003). This 
raises questions about what is happening globally in brain morphology in patients at high risk 
for dementia, moreover for AD. 
 
2.3.3. Imaging in MCI 
 
In recent years, subjects at high risk for developing dementia, or more exactly AD, have been 
intensively studied using in vivo neuroimaging methods, though the results must be 
interpreted with caution taking into account the set of subjects studied and the appropriate 
way of defining them. Even if we concentrate only on MCI subjects, we meet different 
categories of criteria used for collecting the study group, which can influence the results 
obtained in different studies. Furthermore, the neuroimaging protocols employed differ from 
one study to another as well. This thesis will focus rather on ROI-based measurements and 
VBM analyses on brain to review some basic findings in this field. 
 
2.3.3.1. MRI volumetric studies in MCI 
 
Due to the reduced volumes detected by MRI in AD, the ERC and hippocampus have 
consequently been the regions of major interest in MCI. Thus, most of the MRI studies in 
MCI have been dedicated to ROI measurements. An extensive review on neuroimaging in 
MCI stated that the decline in volumes reported in different studies ranged from 13% to 32% 
in the ERC and from 9% to 15% in hippocampus (Wolf et al., 2003) in MCI subjects versus 
controls. Nonetheless, the MCI subjects were chosen based on different criteria in the various 
studies as were the protocols used for measurements of ERC. Therefore, a straight 
comparison between studies is difficult to make. However, the ERC and hippocampal 
volumes are significantly reduced in those subjects determined to be at a transitional stage 
between normal aging and dementia, when compared with controls (Convit et al., 1997; 
Dickerson et al., 2001; Xu et al., 2000; Du et al., 2001). Yet, some investigators reported 
more atrophy in the ERC than in hippocampus (Xu et al., 2000), while others found no 
differences in the magnitude of the volume loss between these two regions (13% versus 11%) 
in MCI versus controls (Du et al., 2001). Convit and colleagues (1997) described a 
hippocampal volume reduction of 14% between subjects with minimal cognitive impairment, 
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termed as MCI and controls. In that study, the MCI subjects were defined according to Global 
Deterioration Scale (GDR) = 3, not using the MCADRC criteria for MCI (Petersen et al.1995; 
Petersen et al., 1999) and there were no reports on the ERC volume. 
 
For defining the boundaries of the ERC, researchers have used different protocols, like that by 
Insausti et al. (1998) in studies by Du et al. (2001) and Xu et al. (2000), but also that by 
Goncharova et al. (2001). With this latter protocol, Dickerson and colleagues (2000) studied 
ERC and hippocampus in subjects "who presented at the clinic with cognitive complaints, but 
did not meet criteria for dementia (non-demented)". As this was a longitudinal study, they 
found that the converters were differentiated from non-converters only by the ERC volume, 
suggesting that the ERC atrophy appears before that of the hippocampus and thus, it is a 
better predictor of conversion. Moreover, the non-demented subjects were better distinguished 
from controls with the ERC volume (69% accuracy) than with the hippocampal volume. Xu et 
al. (2000) reported a more powerful overall classification with the hippocampal volume than 
with the ERC volume, between MCI subjects and controls, while Killiany et al. showed that 
only the ERC volume could discriminate normals from "questionables" (83% accuracy) and 
from converters (84% accuracy) (Killiany et al., 2002). "Questionables" were defined using a 
clinical dementia rating of 0.5 and not the MCADRC criteria for MCI (Petersen et al., 1995; 
Petersen et al., 1999) and the ERC volume in this study was measured from only 3 slices of 
1.5mm each. "Questionables" and converters could not be discriminated with any of these two 
regions. In another study by Killiany et al. (2000) the best discrimination between the groups 
of normal subjects and "questionables" or converters was achieved with the ERC, the banks of 
the supperior temporal sulcus, and the anterior cingulate (accuracy 85%, respectively 93%). In 
that study, no data on the hippocampal atrophy has been reported. 
 
Apart of the two above discussed MRI markers for AD, other regions started more recently to 
gain interest in neuroimaging. The cingulate cortex is part of the limbic system, involved in 
memory functions, and here a severe hypometabolism of glucose rate has been found, 
especially in the hippocampal complex, medial thalamus, mamillary bodies, and posterior 
cingulate, in patients with MCI and mild AD (Nestor et al., 2003). Yet, this is a study using a 
combination between the techniques of MRI with that of positron emission tomography 
(PET). A ROI study reporting the cingulate atrophy in preclinical AD is for instance that of 
Killiany et al. (2000). 
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Results presented by the studies searching for brain atrophy with ROI are in a way limited to 
the fact that, not all of them included subjects defined as MCI according to the probably most 
largely used criteria of MCADRC for MCI (Petersen et al., 1995; Petersen et al., 1999); 
furthermore, the number of subjects was small as for such a heterogenic group; the 
neuroimaging protocols are not constant throughout the studies; and one should beforehand 
plan what brain region to study, thus, significant atrophy may exist and not be detected in 
other regions. For the last inconvenience more recent studies on MCI have employed rather 
semi-, or automatic methods, for example the voxel-by-voxel measurements for detecting 
global brain atrophy. 
 
2.3.3.2. VBM studies in MCI 
 
There are only a few studies employing VBM analysis in MCI (Chetelat et al., 2002; Karas et 
al., 2004; Chetelat et al., 2005; Bell-McGinty et al., 2005), while before the VBM work 
included in this thesis was started there was only one published study on this topic (Chetelat 
et al., 2002). That study applied VBM on 22 patients with amnestic MCI compared to 22 
controls and reported significant gray matter (GM) loss in the hippocampal region, and the 
cingulate gyri, with extension into the temporal neocortex. Bell-McGinty's study had an 
interesting design, presenting not only the GM atrophy in MCI subjects versus controls, but 
also morphologic changes in subgroups of MCI: amnestic group and group with more diffuse 
cognitive impairment (Bell-McGinty et al., 2005). Atrophy in the hippocampus and ERC, and 
in the amygdala and the neocortex was found in the amnestic MCI group of subjects when 
compared to controls. 
 
A recent study reported significant atrophy in global GM of 12.3% in AD compared to 
controls, while the GM atrophy in the MCI group was not significantly different from either 
controls (6.5%) or AD group (6.2%) (Karas et al., 2004). Still, they found a spatial difference 
between the study groups. The atrophy of the MTL, thalamus and insula were significant for 
the MCI group versus that of controls, while the GM atrophy in the parietal association 
cortices and in the cingulate cortex was found in AD versus MCI. Nevertheless, while very 
early thalamic atrophy is not specific for Braak&Braak staging for AD, a glucose 
hypometabolism has been reported to appear early also in this region (Nestor et al., 2003). 
The thalamic involvement in MCI has been shown with VBM analysis (Chetelat et al.2005; 
Chen and Herskovits, 2006). As the VBM can estimate a global GM loss, annual rates ranging 
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from 0% to 4% have been reported during 18 months of follow-up of 18 MCI subjects, with 
the highest rates present in frontal temporal and cingulate cortices in converters, and in frontal 
areas in non-converters (Chetelat et al., 2005). The same group of researchers found an annual 
GM loss of ~4% in the temporal neocortex, 1-2% in the hippocampus and 3-4% in the ERC in 
converters. GM loss has been intensively studied in AD and MCI with ROI and VBM, but it 
seems that this is not the only morphological change in the brain associated with dementia. 
 
2.3.4. WMLs and associations with MCI 
 
There is evidence that the prevalence of white matter lesions (WMLs), defined by volume, 
distribution or substrate increases with age, and while the elevated blood pressure is 
considered to be the strongest predictor of WML, there are also other disease conditions and 
evermore, genetic factors that may contribute to the presence of WMLs (see for review 
Launer, 2003). Moreover, in 51 healthy subjects aged 19 to 91 years without cerebrovascular 
risk factors, the white matter hyperintensity volume was predictive of reduced cognitive 
scores, reduced brain volume and increased ventricular volume (DeCarli et al., 1995). The 
above-mentioned study considered the white matter hyperintensity volume to be abnormal if 
it represented more than 0.5% of the intracranial volume. In a very recent study on dementia- 
and stroke-free subjects, the so called large white matter hyperintensity volume was 
significantly associated with decreased cognitive functioning dependent rather on the frontal 
lobe systems, but also on the medial temporal area, though to a lesser extent (Au et al., 2006). 
Yet, associations between the memory impairment and WMLs remain uncertain, based on a 
study of 40 normal subjects (O'Brien et al., 1997). In a MCI study, apart of APOE є4 and age, 
the white matter hyperintensity volume was also associated with increased risk for MCI, even 
when excluding subjects who had suffered cerebrovascular accidents (DeCarli et al, 2001). 
Wolf and colleagues (2000) found an inverse relationship between WMLs and the temporal 
lobe atrophy in the group of MCI subjects that progressed to dementia during a follow-up 
period of 2-3 years. It has been suggested that WMLs could accelerate the cognitive decline in 
MCI subjects and contribute to the dementia process (Wolf et al., 2000), though a more recent 
longitudinal study reported that WMLs did not predict decline (Korf et al., 2004). Thus, there 
is a need of including the WML burden into both cross-sectional and longitudinal studies on 
MCI to try to achieve a consensus on whether and to what degree those changes contribute to 
the development of dementia in subjects with MCI. 
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2.3.5. MRI volumetry - a predictor of AD in MCI 
 
An annual conversion rate of 6-25% from MCI to AD has been reported, regardless of the 
MCI criteria used in different studies (see for review Petersen et al., 2001 a). For the 
conversion to dementia, respectively to AD in MCI studies different parameters have been 
used: APOE genotype, neuroimaging and neuropsychological batteries, as being in vivo 
predictive markers for AD. The visual assessment of the MTL atrophy was shown to predict 
dementia in MCI subjects independently of age, gender, education, MMSE, CDR sum of 
boxes score, APOE є4, and WML burden (Korf et al., 2004). Important MCI longitudinal 
study designs are both finding predictors to dementia/AD and comparing groups of converters 
with nonconverters as concerns different features. In terms of MTL atrophy and hippocampal 
atrophy significant differences between MCI converters and nonconverters were reported, 
with increased atrophy being seen in decliners (Erten-Lyons et al., 2006). That study did not 
provide data about the entorhinal cortex volume. In a recent longitudinal study with a follow-
up of 5 years, the most important MRI markers for AD, being ERC and hippocampus, were 
examined as predictors for AD, but only the ERC volume and its rate of decline was found to 
be an independent predictor of AD, not the hippocampal volume (Stoub et al., 2005). The 
MCI subjects they studied had been diagnosed according to the Mayo Clinic criteria for 
amnestic MCI (Petersen et al., 1999), and the volumetric MRI protocol used for the ERC 
volume was that developed by Goncharova and colleagues (Goncharova et al., 2001). The 
data reported were obtained from 58 nondemented elderly participants including both 
amnestic MCI subjects and healthy controls with no cognitive impairment, all studied as one 
group. In a review on predictors of conversion to dementia, Modrego suggested that a 
combination of a neuroradiological technique, APOE genotype and cognitive tests may be the 
best option for prediction purposes, until a 100% marker will be detected. Moreover, he 
considered that the ERC and hippocampal atrophy markers are problematic because of 
anatomic variations and artefact possibilities (Modrego, 2006). 
 
2.4. APOE and implications in MCI and AD 
 
2.4.1. What is APOE? 
 
ApoE is a plasma lipoprotein involved in lipid transport and metabolism, which is synthesized 
and secreted by many tissues, primarily liver, but also by brain, as well as by skin and tissue 
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macrophages throughout the body (Saunders et al., 2000). The polymorphism of the human 
APOE gene, located on chromosome 19, consists on 3 different alleles: ε2, ε3 and ε4, whith 
the APOE ε3 being the most common in the general population (77%-78%), while APOE ε2 
represents only 7%-8% and APOE ε4 14%-15% (Cedazo-Miguez and Cowburn, 2001). It is 
known that the human ApoE is a 299 amino acid apolipoprotein, where the three isoforms 
(ApoE2, E3 and E4) differ from one another due to the amino acid changes in positions 112 
and 158. ApoE3 has cysteine at residue 112 and arginine at residue 158, E2 has cysteine at 
residue 112 and 158 and E4 has arginine at residue 112 and 158. The amino acid changes in 
these positions lead to different lipid binding properties and they are responsible for the 
association of each of the isoforms with different diseases (Mahley and Rall, 2000; Cedazo-
Miguez and Cowburn, 2001). 
 
2.4.2. APOE and implications in AD 
 
The presence of the APOE allele ε4 has been the most consistently confirmed genetic risk 
factor for AD (Farrer et al., 1997). In a meta analysis, it was shown that the effect of APOE as 
a major risk factor for AD was seen both in men and women, in all ages between 40 and 90 
years, though the risk effect diminished after the age 70 years (Farrer et al., 1997). Some 
studies have also suggested that AD patients carrying APOE ε4 have more pronounced 
neuropathological changes, exhibit more prominent atrophy of the MTL, and suffer more 
severe memory loss compared to AD patients with no ε4 allele (Lehtovirta et al., 1995; 
Petersen et al., 1995; Alberts, 1996; Lehtovirta et al., 2000; Engelborghs et al., 2003). 
 
Regarding the atrophy of MTL regions in AD, a dose-dependent effect of the APOE ε4 allele 
was shown using ROI-based methods, where atrophy increased significantly from non-
carriers to homozygous carriers via heterozygous carriers (Lehtovirta et al., 1996;  
Juottonen et al., 1998 a; Geroldi et al., 1999). In a study by Boccardi et al. (2004) using VBM 
analysis, some of the MTL regions (amygdala and right hippocampal tail) were atrophied in 
AD carriers of APOE ε4 versus AD non-carriers. Again, using volumetric measurements, 
Lehtovirta and colleagues (1995) showed that amygdaloid damage was greater in AD patients 
homozygous for the ε4 allele, than in heterozygous or noncarriers. 
 
The presence of APOE ε4 has shown a significant role in predicting conversion from MCI to 
AD (Petersen et al., 1995; Alberts, 1996; Kryscio et al., 2006), though there are also data 
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reporting negative results on the predictive value of APOE ε4 for conversion from MCI to AD 
(Korf et al., 2004; Wang et al., 2006). Korf and colleagues presented data showing that visual 
assessment of MTL structures on MRI using a standardized rating scale is a predictor of 
dementia in MCI subjects independently of age, gender, education, MMSE, CDR sum of 
boxes, APOE genotype, and WML burden, while APOE did not predict conversion to 
dementia (Korf et al., 2004). 
 
2.4.3. APOE and implications in MCI 
 
The presence of APOE ε4, as mentioned above, is strongly implicated in the conversion from 
MCI to AD, although there are contradictory results on this topic, but even more, it increases 
the risk of MCI (DeCarli et al., 2001; Lopez et al., 2003; Tervo et al., 2004; Kryscio et al., 
2006). Recently, Fleisher and colleagues found that MCI women carriers of one or two APOE 
ε4 allele have more reduced hippocampal volume than controls, and that this situation in MCI 
men was repeated only for carriers of APOE ε4/ε4 (Fleisher et al., 2005). Earlier, Farlow and 
colleagues reported that the APOE ε4 genotype in MCI subjects was associated with greater 
impairment in memory and functional activities, and a greater decline in the hippocampal 
volume, results that resemble those obtained in AD patients (Farlow et al., 2004). 
Contradictory, Killiany and colleagues found no significant difference in the volume of the 
ERC or the hippocampus in relation to APOE genotype; moreover, the APOE status did not 
add power on the discrimination between groups of controls, questionables, converters and 
AD patients (Killiany et al., 2002). 
 
Of interest is the finding from a longitudinal study of a total of 129 subjects followed-up for 3 
± 1 years, where the proportion of individuals with APOE ε4 increased in the following order 
of clinical outcome: control-stable (10%) < control-decliner (20%) < MCI-stable (28%) < 
MCI-decliner (39%) < AD (46%) (Jack et al., 2000). However, there are conflicting results in 
the literature about APOE and its effect on brain morphology in MCI subjects and on the 
conversion from normal to MCI and to AD. Moreover, little is known about the global effect 
of APOE on the brain, especially on the GM. 
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3. AIMS OF THE STUDY 
 
The focus of this thesis was to concentrate on MCI subjects in the Kuopio MCI study 
applying the hypotheses: those who later convert to AD have lower memory test scores, more 
hippocampal and ERC atrophy and more often have APOE ε4 allele, compared to controls 
and stable MCI subjects. Additionally, MCI carriers of APOE ε4 allele have more profound 
atrophy of the brain than noncarriers, and higher risk to convert to dementia. 
 
The specific aims of studies I-IV were: 
1. To determine whether the ERC atrophy precedes hippocampal atrophy in AD, and to 
evaluate the power of discrimination between the diagnostic groups using MRI volumetry 
(study I). 
2. To map the GM loss in the entire brain of MCI patients using VBM method (study II). 
3. To investigate the difference in the morphologic expression of MCI in subjects carriers and 
noncarriers of the ApoE ε4 allele using the VBM method (study III). 
4. To conduct a follow-up study and to determine what is the predictive value of the MRI-
derived volumes of the hippocampus and ERC, WML, APOE, age, gender, education, MMSE 
and CDR sum of boxes on conversion from MCI into AD (study IV). 
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4. SUBJECTS AND METHODS 
 
4.1. Subjects 
 
The study was approved by the local ethics committee, and all the participants gave informed 
consent for their participation in the study. The original set of the studied subjects was 172, 
including 59 controls, 65 MCI subjects and 48 subjects with AD. The MCI and control 
subjects were derived from two population-based cohorts in whom cognitive functions of the 
elderly had been evaluated (Hänninen et al., 2002 and Kivipelto et al., 2001). AD patients 
were selected from hospital series and were investigated in the Department of Neurology, 
Kuopio University Hospital, Kuopio, Finland. Study I was a volumetric study that used ROI-
based measurements and included the entire set of 172 subjects: 59 controls, 65 MCI subjects 
and 48 subjects with AD. Study II and III used VBM method for inspecting the brain atrophy 
and included 32 controls and 51 MCI subjects, for whom technically adequate scanning 
parameters were available for the VBM method. Study III was designed to assess the brain 
atrophy in MCI subjects related to their APOE genotype. The individuals with MCI were 
divided into three subgroups according to their APOE status: 28 were ε4 noncarriers, 15 were 
heterozygous for the ε4 allele, and 8 were homozygous for the ε4 allele. Study IV included 
60 subjects with MCI for whom clinical follow-up data and brain volumetry data was 
available. The baseline visit included the brain MRI scan in addition to clinical and 
neuropsychological evaluation. There were no reasons for excluding subjects from the study 
on the basis of vascular pathology based on T2 weighted images. Three follow-up visits were 
performed in 1999-2004, and they included neuropsychological tests and clinical neurological 
examination. Finally, the medical history (hospital records) was obtained for those 
participants who did not participate in all study visits to detect the possible conversion to 
dementia. The conversion to dementia was considered as the end-point of the follow-up. 
 
4.1.1. Control subjects  
 
Control subjects were volunteers from the population-based cohorts. They had neither 
dementia nor MCI and were matched by age and gender with the MCI/demented subjects. 
The methods used for the identification of control subjects have been published earlier in 
detail (Hänninen et al., 1997 and Kivipelto et al., 2001). The controls showed no impairment 
in the cognitive tests, and had no history of neurological or psychiatric diseases. 
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4.1.2. AD subjects 
 
The subjects with AD were derived from hospital series of well characterized AD patients 
investigated in the Department of Neurology, Kuopio University Hospital, Kuopio, Finland. 
The diagnostic evaluations for AD patients included medical history, physical and 
neurological examinations performed by a physician, and a detailed neuropsychological 
evaluation administered by a neuropsychologist. The severity of cognitive decline was graded 
according to the CDR Scale (Berg, 1988). Furthermore, brain MRI scan, CSF analysis, ECG, 
chest radiography and blood tests were performed. These were not used in the diagnostic 
phase except for excluding other possible pathologies underlying the symptoms. The 
diagnosis of dementia was based on the criteria of the DSM-IV (American Psychiatric 
Association, 1994) and the diagnosis of AD on the NINCDS-ADRDA criteria (McKhann et 
al., 1984). 
 
4.1.3. MCI subjects 
 
The subjects with MCI were identified from two different population cohorts. In both cohorts, 
the evaluation consisted of a structured interview including the CDR Scale and an extensive 
neuropsychological assessment. The scoring of the CDR was independent of the scores 
obtained from neuropsychological tests. MCI was diagnosed using the criteria proposed by 
Mayo Clinic Alzheimer’s Disease Research Center. Later, these criteria have been modified, 
but at the time this study was conducted the criteria required: (1) memory complaint by 
patient, family, or physician; (2) normal activities of daily living; (3) normal global cognitive 
function; (4) objective impairment in memory or in one other area of cognitive function as 
evident by scores >1.5 S.D. below the age-appropriate mean; (5) CDR score of 0.5; and (6) 
absence of dementia (Petersen et al., 1995 and  Smith et al., 1996). 
 
In the first cohort, the following test battery was used for a comprehensive 
neuropsychological evaluation of different cognitive domains: Memory: Visual Reproduction 
Test (immediate and delayed recall) from Wechsler Memory Scale (Russel, 1975), Logical 
Memory Test (immediate and delayed recall) from Wechsler Memory Scale-Revised 
(Wechsler, 1987), Word List Recall (immediate and delayed recall) from the CERAD 
Neuropsychological Assessment Battery (Morris et al., 1989), delayed recall of the 
Constructional Praxis from CERAD (Morris et al., 1989), New York University Paragraph 
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Recall (immediate and delayed recall) (Kluger et al., 1999); Language: Abbreviated (15 
items) Boston Naming Test (Kaplan et al., 1991), vocabulary subtest from the Wechsler Adult 
Intelligence Scale-Revised (WAIS-R) (Wechsler, 1981); Attention and executive function: 
Verbal Fluency Test (Borkowski et al., 1967 and Butters et al., 1987), Trail Making Test 
(Reitan, 1958) parts A and B; Visuospatial skills: Constructional Praxis from CERAD, Block 
Design from the WAIS-R (Wechsler, 1981); Global functioning: Mini-Mental State 
Examination (Folstein et al., 1975) (MMSE), Clock Drawing Test (the CERAD version) 
(Morris et al., 1989). In this cohort, however, two memory test scores only were used as the 
objective psychometric criteria of memory impairment in MCI diagnosis: according to the 
normative data (Hänninen et al., 2002) in delayed recall in the Logical Memory Test from the 
WMS-R or in the Visual Reproduction Test from the WMS, he or she was defined as 
impaired. All the MCI subjects included in the present study had memory impairment. 
 
The diagnostic procedure used in the second cohort has been previously described in detail 
(Kivipelto et al., 2001). The cognitive functions were screened using the MMSE. Subjects 
scoring < 24 in the MMSE were invited to participate in the clinical phase to assess the 
possibility of MCI. Ultimately, 86% subjects took part in the clinical phase, which consisted 
of taking of medical history, thorough neurologic and cardiovascular examinations performed 
by a physician, and a detailed neuropsychological evaluation conducted by a 
neuropsychologist that included the Buschke Selective Reminding Test (Buschke and Fuld, 
1974), the Logical Memory Test from the Wechsler Memory Scale–Revised (Wechsler, 
1987), the Boston Naming Test (Kaplan et al., 1983), the Vocabulary subtest of the WAIS-R 
(Wechsler, 1981), the Verbal Fluency Test (Borkowski et al., 1967), the Copy a Cube Test 
(Goodglass and Kaplan, 1972), the Clock Setting Test (Goodglass and Kaplan, 1972), the 
Block Design subtest of the Wechsler Adult Intelligence Scale (Wechsler, 1981 b), the 
Wisconsin Card Sorting Test using Nelson’s version (Nelson, 1976), and the Trail Making 
Test (Reitan, 1958). The severity of cognitive decline was graded by the study physician 
according to the CDR scale. A review board consisting of the study physician, the study 
neuropsychologist, and a senior neurologist ascertained the preliminary diagnosis based on all 
available information. As defined by the MCADRC criteria, the cut-off point 1.5 SD below 
the norm in the neuropsychological tests was used as a guideline in the clinical assessment of 
cognitive performance. Thus, both psychometric and clinical aspects were taken into account 
in the ultimate diagnosis of MCI as suggested by the MCADRC criteria. All the MCI subjects 
included in the present study had memory impairment. 
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4.2. Imaging of the brain 
 
4.2.1. MRI and volumetric studies 
 
4.2.1.1. MRI technique for volumetric study 
 
The subjects were scanned with a 1.5 T Siemens scanner (Siemens Magnetom SP or Vision, 
Erlangen, Germany) using a three-dimensional magnetization prepared rapid acquisition 
gradient echo sequence (For the 13 controls and 30 AD patients scanned before year 1998: 
time of repetition (TR) 10 ms, time of echo (TE) 4 ms, matrix 256×256, 1 acquisition and in 
plane resolution=0.98 mm; For 32 controls, 4 AD patients and 51 MCI subjects scanned in 
1998/1999: TR=9.7, TE=4, matrix 256×256, 1 acquisition and in plane resolution=0.98 mm; 
For 14 MCI subjects scanned in 1999/2000/2001: TR=13.5, TE=7, matrix 256×256, 1 
acquisition and in plane resolution=0.94 mm) resulting in contiguous T1-weighted partitions 
with a slice thickness of 1.5-2.0 mm oriented perpendicular to the long axis of the 
hippocampus. The images were then aligned to correct for the undesirable effects of head tilt 
and rotation. Standard neuroanatomical landmarks (such as the orbits, sulci and the 
commissures) were used to correct for possible deviations in any of the orthogonal planes and 
the scans were reconstructed into 2.0 mm thick contiguous coronal slices, oriented 
perpendicular to the intercommissural line. T2 weighted images were also acquired, and used 
to study the possibility of vascular pathology in the cases. 
 
4.2.1.2. Determination of volumes 
 
The hippocampi and ERCs (Figure 2) were manually traced (Figure 3) by a single tracer 
(C.P.), blinded to the clinical data, using custom-made software for a standard Siemens work 
console. The boundaries of the ROI were outlined by a trackball driven cursor and number of 
voxels within the region was calculated by using the in-house developed program for standard 
work console. Thus, once the ROI had been traced, the software calculates the volume for 
every structure by computing the number of voxels for each traced image. The outlining of 
the boundaries always proceeded from anterior to posterior. Data from a standard anatomical 
atlas of the human brain (Duvernoy, 1999), and from previous articles were used as guidelines 
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to determine the boundaries of the hippocampus (Laakso et al., 1998) and the ERC (Insausti 
et al., 1998). 
Figure 2. Hippocampus and ERC in controls, MCI, mild AD and moderate AD 
 Control    MCI 
  
 
 Mild AD                   Moderate AD 
  
 
Figure 3. ROI-volumetry of the left ERC and right hippocampus 
 
 
4.2.1.3. Measurement of the hippocampal volume 
 
Tracing of the hippocampus started rostrally where the hippocampus first appears below the 
amygdala and ended posteriorly in the section where the crura of the fornices depart from the 
lateral wall of the lateral ventricles. The hippocampus included the dentate gyrus, the 
hippocampus proper and the subicular complex. 
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4.2.1.4. Measurement of the ERC 
 
The ERC volumes were traced according to the histology-based criteria designed for MRI 
volumetric measurements (Insausti et al., 1998). In brief, the most anterior slice measured was 
the one after the appearance of the temporal stem, and the last slice was the one where the 
uncus and gyrus intralimbicus were no longer separable. 
 
4.2.1.5. Measurement of the ICA 
 
The coronal intracranial area (ICA) was measured at the level of the anterior commissure and 
it was used for normalization of the volumetric data. For the purpose of data presentations, the 
volumes were normalized to the intracranial area according to the formula: 
(volume/intracranial area) × 100. 
 
4.2.1.6. Validation studies 
 
The intraclass correlation coefficients for intrarater reliability were 0.96 for the hippocampus 
and 0.95 for the ERC measured from 10 subjects. 
 
4.2.2. VBM 
 
In the VBM method, the brains of groups of subjects are modified in a pre-processing phase, 
in order to fit a reference template, such that a stereotactic point refers to the same structure in 
each normalized brain. Then automatic statistical analyses are carried out, that compare the 
concentration of gray matter in each voxel. 
 
4.2.2.1. VBM pre-processing 
 
After removing the voxels below the cerebellum with MRIcro software 
(www.psychology.nottingham.ac.uk/staff/cr1/mricro.html) (Rorden and Brett, 2001) the MR 
images were analysed with Statistical Parametric Mapping (SPM99) 
(www.fil.ion.ucl.ac.uk/spm) running under Matlab 5.3 (Mathworks, Sherborn, MA, USA).  
 
46 
The MR images were pre-processed following a protocol, which included (1) generation of a 
customised template, (2) generation of customised prior probability maps, and (3) the main 
VBM steps (Figure 4): normalisation of the original MR images, segmentation of normalised 
images, cleaning of grey matter images, modulation of grey matter images, and smoothing of 
modulated images. 
 
Figure 4. Main VBM steps, after LENITEM. 
a).                                                                         b). 
template
Native MR subj. 1 Native MR subj. 2
VBM – NORMALISATION
Normalised MR subj. 1 Normalised MR subj. 2      
CSF
White matter
Normalised MR 
Gray matter
VBM – SEGMENTATION
  
 
 
  c). 
  
VBM – MODULATION
VBM – CLEANING
GM
 
   
 
The advantages of this procedure over the traditional simple protocol are that (1) the use of 
template and prior probability maps computed from the population under study reduces the 
error in the normalisation and segmentation steps, (2) the cleaning step permits removal of 
non-brain voxels erroneously classified as grey matter (Good et al., 2002), and (3) modulation 
permits preservation of the original volume of grey matter within each voxel (Ashburner and 
Friston, 2000; Ashburner and Friston, 2001; Good et al., 2001 b). 
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(1) Customised template 
The customised template was obtained by normalising the images of the 51 MCI patients and 
32 controls to the Montreal Neurological Institute template (Evans et al., 1994) of SPM99 
using a 12 parameter affine transformation, smoothing the normalised images with an 8 mm 
isotropic Gaussian kernel and averaging the smoothed images. The anterior commissure was 
manually set as the origin of the spatial coordinates and images were reoriented coronally 
perpendicular to the intercommissural line. The normalisation procedure uses a bilinear 
interpolation algorithm to reslice images to a voxel size of 2x2x2 mm. This voxel size was 
used in the following processing and analysis. 
 
(2) Customised prior probability maps 
Customised prior probability maps were computed by segmenting the normalised images into 
GM, white matter (WM), and CSF, then smoothing with an 8 mm Gaussian filter, and finally 
averaging the segmented images, thus obtaining the customised prior probability maps 
specific for GM, WM, and CSF (Good et al., 2002). The voxels, which probability of being 
brain was greater than 0.5 were smoothed with an 8-mm isotropic Gaussian kernel in order to 
create the customized brain mask. 
 
(3) Main VBM steps 
Original images were normalised to the customised template through affine and non-linear 
transformations, medium regularisation, reslicing 2x2x2 mm, and no masking (Baron et al., 
2001). The normalised images were segmented into GM, WM, and CSF using the customised 
prior probability maps. The Xbrain routine, based on erosions and dilatations, was used to 
remove voxels of non-brain tissue from the segmented images, thus obtaining a brain mask to 
clean the GM images by intersection with the mask. In the modulation step, voxel values of 
the cleaned GM images were multiplied by the measure of relative volumes of warped and 
unwarped structures derived from the non-linear step of spatial normalisation (Jacobian 
determinant) (Good et al., 2002). The modulated GM images were smoothed with a 12 mm 
isotropic Gaussian kernel. The final output is a 3D matrix where the three indices are the 
spatial x, y, and z coordinates of voxels in the reference space, and each value of the matrix is 
proportional to the volume of GM within each voxel. It should be emphasised that the output 
of each stage of the analysis was visually checked to ensure that the algorithms had actually 
carried out the expected changes. 
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4.2.3. Determination of WMLs 
 
The WMLs were evaluated by a single rater (R.R.) on MRI images on a computer screen with 
either proton density (PD) and T2 weighted images or on T2 or FLAIR images by using the 
rating scale by Wahlund et al. (2001). The WMLs were defined as bright lesions ≥5 mm on 
T2, PD or FLAIR images. In frontal, temporal, parieto-occipital, and infratentorial regions, 
WMLs were scored: 0 = no lesions (including symmetrical, well-defined caps or bands), 1 = 
focal lesions, 2 = beginning of confluence of lesions, 3 = diffuse involvement of the entire 
region; and in the basal ganglia: 0 = no lesions, 1 = one focal lesion (≥5 mm), 2 = more than 
one focal lesion, 3 = confluent lesions. The sum score of frontal, temporal, parieto-occipital, 
basal ganglia, and infratentorial regions were used in the analysis. 
 
4.3. Determination of APOE genotype 
 
APOE genotype was determined from blood leukocytes. DNA was extracted by a standard 
phenol-chloroform extraction, and APOE genotypes were analyzed by polymerase chain 
reaction and HhaI digestion as described previously (Tsukamoto et al., 1993). 
 
4.4. Statistical analyses 
 
4.4.1. MRI volumetric analyses 
 
Study I 
The statistical software SPSS for Windows V10.0 (SPSS Inc., Chicago, IL) was used to 
analyze the data. In all statistical analyses of the volumetric data, volumes normalized for the 
intracranial area we used. One-way ANOVA with Bonferroni post hoc analysis was used to 
compare the means of age, education, and MMSE scores between the groups. The relationship 
of volumes with gender, diagnostic groups and age was assessed with the ANCOVA test, 
which had hippocampal and ERC volumes as dependent variables, gender and diagnostic 
groups as factors, and age as covariate. Pearson’s correlation coefficients were used to 
analyze the correlation between the hippocampal and ERC volumes within each study group. 
We tested the value of the hippocampal and ERC volumes in discriminating between the 
groups using discriminant analyses with enter and stepwise methods, respectively. In the 
analyses, the normalized volumes to the intracranial area and adjusted for age were used. 
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First, discriminant analyses with an enter method were used to analyze the value of 
normalized total volumes of the hippocampus and ERC to distinguish AD patients or MCI 
subjects from controls and MCI subjects from patients with AD, using volumes as 
independent variables. Then, the value of the hippocampal and ERC total volumes for group 
classification were tested using stepwise discriminant function analyses (Wilks’ method). 
Finally, stepwise discriminant analysis was used to test unilateral volumes: the right and left 
hippocampal volume, the right and left ERC volume in discrimination between pairwise 
combinations of clinical groups. The results are expressed as mean±S.D. The level of 
statistical significance of differences is P<0.05. The discrimination between groups was also 
represented with ROC curves. 
 
Study IV 
The statistical software SPSS for Windows V11.5 (SPSS Inc., Chicago, IL) was used to 
analyze the data. In all statistical analyses of the volumetric data, we used volumes 
normalized for the intracranial area. Student's T test was used to assess group differences. The 
effect of side (within group variable) and outcome (between-group variable) on the volumes 
of the hippocampus and ERC was assessed by ANOVA. Interaction terms were included in 
the model as needed. Because of the variability in the follow-up length, the predictive 
accuracy of volumetry for dementia was assessed by Cox’s regression analysis with follow up 
time as the time variable and conversion to dementia or AD as the status variable. The hazard 
ratios (HR) with 95% CI and significance (p value) are presented. The level of statistical 
significance of differences was set at p<0.05. 
 
4.4.2. VBM analyses 
 
Study II 
A "Single subject: Conditions and Covariates" model was used to compare the volume of GM 
between MCI and controls on a voxel by voxel basis. The analysis was controlled for APOE 
genotype including genotype (ε3/3, ε3/4 , and ε4/4) as a dummy variable. Intracranial area, 
age, and sex were included as nuisance covariates. The resulting t map was thresholded at 
p<0.001, uncorrected. The demographic and clinical data were analysed using one way 
ANOVA or χ2 test, the level of significance was set at p<0.05. 
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Study III 
The individuals with MCI were divided into three subgroups according to their APOE status: 
28 were ε4 noncarriers, 15 were heterozygous for the ε4 allele, and 8 were homozygous for 
the ε4 allele. The "Single subjects – Conditions and Covariates" procedure was used to 
compare the gray matter volume between MCI and controls and between MCI carrying and 
not carrying the ε4 allele. Intracranial area, age and sex were included as nuisance covariates. 
The regions atrophic in individuals heterozygous and homozygous for the APOE ε4 allele 
were detected by contrasting all MCI subjects to controls and inclusively masking atrophy of 
individuals heterozygous and homozygous for the APOE ε4 allele relative to noncarriers. This 
approach allows detecting areas of atrophy of noncarriers related to both heterozygous and 
homozygous carriers of the ε4 allele. The resulting t map was thresholded at p<0.001, 
uncorrected. 
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5. RESULTS 
 
5.1. Descriptive characteristics 
 
The groups from study I were well matched for age (F=1.5, P=0.24) and gender (χ2=2.4, 
p=0.30). The MMSE scores declined in the following order: control>MCI>AD (p<0.001) 
(Table 1). The level of education differed significantly across the study groups (F[2,164]=4.3, 
p<0.05); the subjects with MCI had significantly a lower level of education compared to 
controls (Bonferroni post hoc analysis P<0.05). 
 
In study II there was no difference in age (F = 1.96, p = 0.17), sex (χ2 = 0.45, p = 0.50), 
education (F = 0.20, p = 0.66), or frequency of the APOE ε4 allele (χ 2 = 2.5, p = 0.11) 
between the controls and cases with MCI. As expected, the Mini-Mental State Examination 
scores were significantly lower in cases with MCI compared with the controls (F = 24.8, 
p<0.0001) (Table 2). 
 
In study III the groups of MCI individuals according to the APOE polymorphism were also 
matched for age, gender and MMSE (Table 2). 
 
For the subjects from study IV, the mean follow-up time was 34 (SD 8.7, range 10 to 54) 
months. During this period, 13 (21.7 %) patients had progressed to dementia (progressive 
MCI). Nine (69%) patients in this group had a clinical diagnosis of probable AD, three had 
vascular dementia and one had dementia of mixed type. In the stable MCI group, seven 
subjects had a neuropsychological profile of control subjects in the last follow-up visit. At 
baseline, there were no differences between the outcome groups in education, age, MMSE 
score (Table 2), follow-up time [months as mean (SD): 35.2(8.2) for the stable MCI group 
versus 30.7(9.9) for the progressive MCI group], or in the WML load [mean (SD): 4.2(4.5) in 
the stable MCI group versus 4.5(2.9) in the progressive MCI group]. Patients with stable MCI 
had lower (p<0.05) CDR sum of boxes [1.2(0.5), for subjects n=45] compared to patients with 
progressive MCI [2.1(1.1), for subjects n=12]. The progressive MCI group included eight 
patients with at least one APOE ε4 allele. Three patients were heterozygous for the APOE ε 
allele (ε3/ε4) and five were homozygous (ε4/ε4). Five patients with the progressive MCI were 
ε4 non-carriers (ε3/ε3). The stable MCI group consisted of 21 APOE ε4 allele carriers. 
Eighteen of them were heterozygous for the APOE ε4 allele (17 ε3/ε4, 1 ε2/ε4), and three 
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were homozygous. Twenty-six subjects in the stable MCI group were ε4 non-carriers (25 
ε3/ε3, 1 ε2/ε3). The APOE groups (at least one ε4 allele, no ε4 allele) did not differ in age, 
education, follow-up time, baseline MMSE score, or CDR sum of boxes in progressive MCI. 
In subjects with stable MCI the only statistically significant difference was found in the 
follow-up time as subjects without the APOE ε4 allele had a longer follow-up time compared 
to subjects with ε4 allele (mean ± SD: 37.9 ± 5.46 versus 31.7 ± 9.79, p < 0.05). 
 
Table 2. Descriptive characteristics 
 
 CONTROLS     MCI   AD 
Study I II&III I  II&III   IV I 
    є-/- є4/- є4/4 stable progressive  
Number 59 32 65 28 15 8 47 13 48 
Age 73(4) 74(4) 73(5)  72(5)  73(4) 72(4) 71(8) 
    73(4) 71(5) 70(3)    
Sex 37(63) 19(59) 43(66) 17(61) 13(87) 4(50) 33(70) 8(62) 25(52)
Education 8(3) 7(2) 7(2)  7(2)  7(2) 7(2) 7(3) 
MMSE 27(2) 27(2) 24(3)  24(2)  24(3) 23(2) 21(4) 
    24(4) 24(3) 23(2)    
ApoEє4+/- 13/45 9/22 30/35  23/28  21/26 8/5 32/16 
MCI: mild cognitive impairment; AD: Alzheimer’s disease; MMSE: Mini-Mental State 
Examination; Sex: female (%); Age, Education and MMSE expressed as mean (SD); 
ApoEє4+/-: carriers of at least one ApoE є4 allele / noncarriers. For one control subject, the 
ApoE genotype is not known. 
 
 
5.2. MRI volumetry of hippocampus and ERC in controls, AD subjects and MCI 
subjects (study I) 
 
The objective in this study was to determine the volumetric differences for the hippocampus 
and the ERC between the study groups of controls, MCI and AD. Moreover, we intended to 
determine the power in discrimination between the study groups for unilateral and total 
volumes of hippocampus and ERC. 
 
5.2.1. Comparative volumetric measurements in controls, AD subjects and MCI subjects 
 
The diagnostic groups (controls, MCI and AD) differed significantly in the volumes 
(F[2,164]=88.2, p<0.001 for hippocampal volume; F[2,164]=50.1, p<0.001 for ERC volume), 
gender had no influence on the volumes (F[1,164]=1.1 for hippocampal volume, 
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F[1,164]=0.03 for ERC volume, p>0.05), gender×group had no influence on the volumes 
(F[2,164]=0.2 for hippocampus, F[2,164]=2.3 for ERC volume, p>0.05), and age did not 
affect the hippocampal volume (F[1,164]=2.6, p>0.05), but it did affect the ERC volume 
(F[1,164]=8.2, p=0.01). While age was not correlated with total ERC volume in the control 
group (r=−0.23, p=0.09) or in the MCI group (r=−0.15, p=0.22), in the group of patients with 
AD there was a significant correlation between age and the total ERC volume (r=−0.30, 
p=0.04). Therefore, all the analyses were adjusted for age. 
 
The total hippocampal volume and the total ERC volume, as well as the unilateral volumes of 
hippocampus and ERC were significantly reduced in the following order: control>MCI>AD 
(Table 3). The total hippocampal and total ERC volumes were correlated within each group 
(control: r=0.35, p=0.01; MCI: r=0.53, p<0.001; AD: r=0.58, p<0.001). 
 
Table 3. Volumetric measurements and percentual decrease in volume 
 
Controls                MCI                 AD Region 
 Volume Volume Decrease (%) Volume Decrease (%) 
Hippocampus 
Right 16.37±2.19 15.20±2.51*   7 10.55±2.86§‡ 36 
Left 15.36±2.23 13.90±2.54† 10   9.34±2.48§‡ 39 
Total 31.73±4.19 29.10±4.77†   8 19.90±5.10§‡ 37 
Entorhinal cortex 
Right   9.02±1.89   7.65±1.59† 15   5.88±1.92§‡ 35 
Left   8.47±1.94   7.00±1.50† 17   5.29±1.62§‡ 38 
Total 17.49±3.63 14.66±2.96† 16 11.18±3.20§‡ 36 
The analyses represent normalized volumes. The results are expressed as mean±S.D. and the 
decrease % is compared with controls. Right: right side; Left: left side; Total: sum of the right 
plus left side volumes; MCI: mild cognitive impairment; AD: Alzheimer’s disease. 
*p < 0.05 for MCI vs. controls 
§p < 0.001 for AD vs. MCI 
‡p < 0.001 for AD vs. controls 
†p < 0.001 for MCI vs. controls 
 
 
54 
The percentual decrease in ERC volume was higher compared to that in the hippocampal 
volume in the MCI group versus controls, whereas the volume losses in the AD group versus 
controls were of the same magnitude for the hippocampus and ERC (Figure 5). 
 
Figure 5. The percentual decrease of total ERC and total hippocampal (HC) volumes within  
each study group relative to mean volumes for the control group. The 95% CI is considered. 
 
 
 
 
5.2.2. Discriminant function analyses 
 
In discriminant function analysis, we used first the enter method for the volumes of the total 
(right and left) hippocampus and total (right and left) ERC, adjusted for age and thereafter a 
stepwise method to test the accuracy of first total and thereafter unilateral volumes in 
classifying the groups (Table 4). 
 
In the classification between MCI subjects and controls, the volume of the total hippocampus 
yielded an overall classification of 59.7% (Wilks’ λ=0.92, χ2=10.1, p=0.01), the volume of the 
total ERC yielded an overall classification of 66.7% (Wilks’ λ=0.84, χ2=21.3, p<0.001). In the 
stepwise analysis, only the total ERC volume entered the model with an overall classification 
of 65.9% (Wilks’ λ=0.84, χ2=21.0, p<0.001). In the stepwise discriminant function analysis 
including unilateral hippocampal and ERC volumes only left ERC volume entered the model 
(Wilks’ λ=0.85, χ2=20.3, p<0.001) (Table 4). 
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Distinguishing AD patients from control subjects, the volume of total hippocampus yielded an 
overall classification of 90.7% (Wilks’ λ=0.36, χ2=105.1, p<0.001), the total ERC volume 
yielded an overall classification of 82.1% (Wilks’ λ=0.50, χ2=70.8, p<0.001). In the stepwise 
analysis both the hippocampal volume and the ERC volume entered the model (overall 
classification 90.6%, sensitivity 87.6%, specificity 93.1%; Wilks’ λ=0.34; χ2=111.1; 
p<0.001). In the stepwise discriminant function analysis including unilateral hippocampal and 
ERC volumes, the left hippocampal volume and the right ERC volume entered the model 
(Wilks’ λ=0.35, χ2=108.1, p<0.001) (Table 4). 
 
Table 4. Classification between the groups using discriminant function analysis with the  
enter method including in the model hippocampus (HC), or entorhinal cortex (ERC), as  
well as with the stepwise method including in the model both the HC and ERC 
 
Groups and variables Sensitivity % Specificity % Overall classification % P 
MCI and Controls 
Enter: HC 56.9 62.7 59.7 0.01 
Enter: ERC 63.1 70.7 66.7 <0.001
Stepwise: ERC 66.2 65.5 65.9 <0.001
AD and Controls 
Enter: HC 85.4 94.9 90.7 <0.001
Enter: ERC 85.4 79.3 82.1 <0.001
Stepwise: HC + ERC 87.6 93.1 90.6 <0.001
AD and MCI 
Enter: HC 77.1 83.1 80.5 <0.001
Enter: ERC 70.8 70.8 70.8 <0.001
Stepwise: HC 81.3 83.1 82.3 <0.001
The analyses included the bilaterally summed and normalized volumes adjusted for age. 
MCI: mild cognitive impairment; AD: Alzheimer’s disease. 
 
 
Distinguishing AD patients from MCI subjects, the total hippocampal volume showed an 
overall classification of 80.5% (Wilks’ λ=0.52, χ2=72.0, p<0.001), the ERC volume yielded 
an overall classification of 70.8% (Wilks’ λ=0.73, χ2=34.1, p<0.001). In the stepwise analysis, 
only hippocampal volume entered the model (overall classification 82.3%, sensitivity 81.3%, 
specificity 83.1%; Wilks’ λ=0.53, χ2=69.3, p<0.001). In the stepwise discriminant function 
analysis including unilateral hippocampal and ERC volumes, only left hippocampal volume 
entered the model (Wilks’ λ=0.55, χ2=66.0, p<0.001) (Table 4). 
 
ROC curves were used to illustrate the discrimination between groups with hippocampal and 
ERC volumes (Figure 6). 
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Figure 6. ROC curves representing discriminations between groups with MRI volumetry: a). 
control-MCI; b). control-AD; c). MCI-AD 
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c). 
 
 
5.3. VBM analyses in MCI subjects (study II) 
 
The objective of this study was, using APOE genotype as a confounding factor, to determine 
the pattern of brain atrophy in MCI subjects. 
 
MCI subjects exhibited the greatest atrophy in the right hippocampus-amygdala region, and in 
the right hippocampal tail and thalamus, when compared to controls (Figure 7, Table 5). The 
medial temporal structures on the left did not quite achieve the level of statistical significance. 
Other regions with significant gray matter atrophy were detected in the right superior temporal 
gyrus, the left thalamus, the left inferior temporal gyrus, and the left anterior cingulate gyrus 
(Table 5). 
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Table 5. Atrophic regions of MCI cases compared with controls (p<0.001, uncorrected) 
 
Stereotactic  
coordinates (mm)
 
Cluster size k 
 
Region 
x y z 
 
Z score 
147 Right thalamus 12 –14 12 3.74 
 Right hippocampus (tail) 24 –34 4 3.42 
 Right thalamus 16 –26 0 3.31 
246 Right amygdala-hippocampus 24 –4 –16 3.72 
14 Left superior parietal lobule –16 –60 66 3.36 
10 Right superior temporal gyrus 56 8 –6 3.31 
6 Left thalamus –8 –14 12 3.27 
15 Left anterior cingulate gyrus –10 2 42 3.24 
2 Left inferior temporal gyrus –66 –20 –28 3.16 
10 Left thalamus –16 –30 8 3.14 
Region denotes the areas of maximal grey matter volume loss within each cluster. For 
example: the first line denotes the presence of a 3D cluster created from 147 contiguous 
voxels of significantly decreased (p<0.001) gray matter volume. Within the same cluster, 
there are two more peaks of significance more than 8 mm from the former and located at 24, –
34, 4 and at 16, –26, 0. The most significant voxel of the cluster has stereotactic coordinates 
of 12, –14, and 12 and is located in the region of the right thalamus. 
 
Figure 7.  Medial temporal involvement in MCI patients compared with controls with 
p<0.001, uncorrected. Significant voxels are superimposed on MR images of a single control 
subject. Atrophy affects the amygdala and the head and tail of the hippocampus. 
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5.4. VBM analyses in MCI subjects, carriers of APOE є4 (study III) 
 
The objective of this study was to determine first the pattern of brain atrophy in MCI subjects 
with no APOE confounding used, thereafter to map the gray matter loss in MCI subjects 
carriers of APOE ε4. 
 
MCI subjects exhibited the greatest atrophy in the right and left amygdala, right 
parahippocampal gyrus, left medial dorsal thalamic nucleus and right superior temporal gyrus, 
when compared to controls (Figure 8, Table 6). 
 
Figure 8. Regions of atrophy in MCI. a Atrophy in 15 MCI with one ε4 allele compared to 28 
MCI without APOE ε4. b Atrophy in 8 MCI with 2 ε4 alleles compared to 28 MCI without 
APOE ε4. 
 
   
 
 
In the comparison between MCI individuals heterozygous for the APOE ε4 allele and 
noncarriers only the right parahippocampal gyrus, with the ERC included, reached the level of 
statistical significance (Figure 8 a, Table 6). The most significant atrophy between 
homozygous for the ε4 allele and noncarriers was located in the right amygdala followed by 
the right parahippocampal gyrus, the left amygdala and the left medial dorsal thalamic 
nucleus (Figure 8 b, Table 6). 
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When compared to controls, APOE ε4 noncarriers showed the widest and most significant 
clusters of atrophy in the parahippocampal gyrus bilaterally (on the right: cluster size 102 
voxels, coordinates 24, –36, 2, z = 3.73; on the left : cluster size 34 voxels, coordinates –22, –
4, 14, z = 3.31) and in the left medial dorsal thalamic nucleus (cluster size 24 voxels, 
coordinates –6, –14, –12, z = 3.43). Other smaller clusters were located in the temporoparietal 
regions bilaterally. 
 
Table 6. Atrophic regions of MCI subjects compared to controls (p<0.001 uncorrected) and 
of MCI subjects in study groups subdivided according to the APOE genotype 
 
Stereotactic  
coordinates (mm)
 
Cluster size k 
 
Region 
x y z 
 
Z score 
MCI versus controls 
326 Right amygdala  26  -6  18 3.81 
152 Right parahippocampal gyrus  24 -36   2 3.73 
 24 Left medial dorsal thalamic nucleus  -6 -14  12 3.43 
 53 Left amygdala -22  -4 -14 3.31 
  3 Right superior temporal gyrus  56   8  -6 3.17 
MCI ε 4+/– versus MCI ε 4–/– 
  1 Right parahippocampal gyrus  18 -40    6 3.10 
MCI ε 4 +/+ versus MCI ε 4 –/– 
326 Right amygdala  26  -6 -18 3.81 
133 Right parahippocampal gyrus  24 -36   2 3.73 
 52 Left amygdala -22  -4 -14 3.31 
  2 Left medial dorsal thalamic nucleus  -6 -16   8 3.18 
  1 Left medial dorsal thalamic nucleus  -4 -14  10 3.14 
Cluster size is given in number of voxels. Region denotes the areas of maximal grey matter 
volume loss within each cluster. For example, the first line denotes the presence of a 3D 
cluster created from 326 contiguous voxels of significantly decreased (p<0.001) gray matter 
volume, with stereotactic coordinates of 26, -6, 18 and located in the right amygdala. 
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5.5. Predictors of AD in MCI subjects (study IV) 
 
The aim of this study was to determine the hippocampal and ERC volume loss in those MCI 
subjects that progressed to dementia, or to AD during a period of mean follow-up time of 34 
months, a group so called "progressive MCI" compared to those MCI subjects that did not 
convert to dementia, so called "stable MCI". One additional objective of this longitudinal 
study was to determine the predictive value of the MRI-derived volumes of MTL structures, 
WML, severity of cognitive impairment, and APOE genotype on conversion of MCI to 
dementia and AD. 
 
5.5.1. Volumetric measurements at baseline 
 
At baseline, patients with progression of MCI to dementia had significantly reduced (p<0.01) 
volume of the right hippocampus and the right ERC (Table 7) versus patients with stable 
MCI. A similar trend was found in the analysis of the volumes of the left hippocampus and 
the left ERC, but this difference did not reach statistical significance. However, the total 
volume (sum of the right and left side) of the hippocampi and the ERCs were significantly 
reduced (p<0.05) in the progressive MCI group vs. stable MCI group (Table 7). The lowest 
volumes were found in patients with progression of MCI to AD (right hippocampus: 12.9 ± 
2.4, left hippocampus: 12.2 ± 2.7, right ERC: 6.1 ± 1.3, left ERC: 5.8 ± 0.6), and all of the 
analyzed volumes were significantly reduced (p<0.05) compared to the stable MCI group. 
 
In the progressive MCI group there was a tendency of decreased volumes in those patients 
with at least one APOE ε4 allele, and the volumes of the left hippocampus and the total 
volume of the hippocampi reached statistical significance (p<0.05) (Table 7, Figure 9). In the 
group of stable MCI, there were no significant differences in the volumes of hippocampi or 
ERCs in the APOE groups. 
 
In the progressive MCI group, patients with at least one ε4 allele had significantly reduced 
total volumes in hippocampus and ERC as well as lowered volumes of the right and the left 
side separately (p < 0.05) compared to subjects with stable MCI with at least one ε4 allele 
(Table 7, Figure 9). On the other hand, there were no differences in these volumes between 
the stable or progressive MCI groups in the subjects without the APOE ε4 allele (Figure 9). 
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Table 7. Volumes of hippocampus and ERC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results are mean (SD). HC: normalized volume of the hippocampus; ERC: normalized 
volume of the entorhinal cortex; Total: sum of the right plus left side volumes; APOE ε4+/ε4-
: at least one APOE ε4 allele/ no APOE ε4 allele.  
* p < 0.05; # p < 0.01 
 
 
 
 
 
 
 
 
 
 Stable MCI Progressive MCI 
Right HC 15.52 (2.36) 13.53 (2.26) # 
      APOE ε4+ 14.99 (2.48) 12.75 (2.38) 
      APOE  ε4- 15.96 (2.20) 14.79 (1.51) 
Left HC 14.19 (2.25) 12.80 (2.68) 
      APOE ε4+ 13.96 (2.02) 11.26 (2.03) 
      APOE  ε4- 14.38 (2.43) 15.27 (1.42) 
Total HC 29.71 (4.42) 26.33 (4.54)* 
      APOE ε4+ 28.94 (4.39) 24.01 (3.83) 
      APOE  ε4- 30.34 (4.42) 30.06 (2.81) 
Right ERC 7.91 (1.56) 6.62 (1.44) # 
       APOE ε4+ 7.96 (1.73) 6.11 (0.95) 
       APOE  ε4- 7.87 (1.44) 7.42 (1.82) 
Left ERC 7.11 (1.53) 6.44 (1.45) 
       APOE ε4+ 7.22 (1.37) 5.88 (0.75) 
       APOE  ε4- 7.02 (1.68) 7.34 (1.91) 
Total ERC 15.02 (2.98) 13.06 (2.74)* 
       APOE ε4+ 15.17 (3.00) 12.00 (1.59) 
       APOE  ε4- 14.90 (3.02) 14.76 (3.50) 
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Figure 9. Total volumes of the hippocampus and entorhinal cortex (EC) in stable and 
progressive MCI in subjects with at least one APOE ε4 allele or without any ε4 allele. Filled 
circles represent patients with conversion of MCI to AD during the follow-up period. 
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5.5.2. Predictors for conversion to dementia 
 
In the univariate Cox’s regression analysis, the volumes of the hippocampus and ERC on the 
right side, the total volume of the hippocampi, and the CDR sum of boxes significantly 
predicted the progression of MCI to dementia (Table 8). The baseline MMSE score, WML 
burden, or the APOE ε4 allele were not significant predictors of progression. When patients 
with non-AD dementia were excluded, the right, left and total hippocampal and ERC volumes 
significantly predicted the progression to AD (Table 8). In this analysis CDR sum of boxes, 
MMSE scores, WML burden or APOE ε4 allele were not significant predictors for AD. 
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Table 8. Cox’s univariate regression analysis with follow-up (months) as time variable and 
outcome (Dementia, AD) as status variable 
 
 Dementia  AD  
Right HC 0.738 (0.58 - 0,94) * 0.668 (0.49 - 0.91) # 
Left HC 0.866 (0.68 - 1.10) 0.739 (0.55 - 1.00) ** 
Total HC 0.881 (0.77 -1.00) ** 0.815 (0.69 - 0.97) * 
Right ERC 0.597 (0.38 - 0.93)* 0.439 (0.25 - 0.77)# 
Left ERC 0.836 (0.56 - 1.24) 0.568 (0.34 - 0.95)* 
Total ERC 0.824 (0.65 - 1.04) 0.651 (0.47 - 0.90)# 
Age 0.991 (0.87 - 1.12) 0.972 (0.84 - 1.12) 
Gender 0.625 (0.20 - 1.98) 0.543 (0.15 - 2.04) 
MMSE at baseline 0.919 (0.73 - 1.16) 0.918 (0.70 - 1.20) 
CDR sum of boxes 2.730 (1.55 - 4.81)##  1.948 (0.90 - 4.21) 
Education 0.979 (0.68 - 1.42) 1.198 (0.78 - 1.84) 
APOE ε4 allele 0.534 (0.17 - 1.69) 0.359 (0.89 - 1.44)  
WML load 1.007 (0.89 - 1.14) 1.016 (0.88 - 1.17) 
Results are expressed as Hazard Ratio (95 % confidence interval). HC: normalized volume of 
the hippocampus; ERC: normalized volume of the entorhinal cortex; total: sum of the right 
plus left side volumes; AD: conversion of MCI to Alzheimer's disease; MMSE: Mini-Mental 
State Examination; CDR: Clinical Dementia Rating Scale; WML: white matter lesions. 
* p < 0.05 
** p = 0.05 
# p < 0.01 
## p < 0.001 
 
 
In bivariate Cox’s regression analysis, the CDR sum of boxes and the volumes of the right 
ERC remained significantly associated with progression of MCI to dementia, whereas 
progression of MCI to AD was significantly associated only with the baseline volumes of the 
ERCs (Table 9). 
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Table 9. Cox’s bivariate regression analysis with follow-up (months) as the time variable and 
outcome (Dementia, AD) as the status variable 
 
 Dementia  AD  
Right HC 
CDR sum of boxes 
0.805 (0.61 - 1.07) 
2.627 (1.43 - 4.84)#  
0.731 (0.52 - 1.03) 
1.685 (0.71 - 4.00) 
Left HC 
CDR sum of boxes 
0.952 (0.73 - 1.24) 
2.721 (1.53 - 4.83) ## 
0.812 (0.59 - 1.11) 
1.829 (0.80 - 4.17) 
Total HC 
CDR sum of boxes 
0.932 (0.81 -1.07) 
2.675 (1.48 - 4.84) ## 
0.864 (0.72 - 1.03) 
1.723 (0.73 - 4.05) 
Right ERC 
CDR sum of boxes 
0.577 (0.35 - 0.94)* 
3.124 (1.67 - 5.86) ## 
0.448 (0.24 - 0.83) # 
2.222 (0.93 - 5.33) 
Left ERC 
CDR sum of boxes 
0.787 (0.50 - 1.24) 
3.001 (1.60 - 5.64) ## 
0.542 (0.30 - 0.97)* 
2.268 (0.93 - 5.50) 
Total ERC 
CDR sum of boxes 
0.799 (0.62 - 1.02) 
3.175 (1.67 - 6.05) ## 
0.658 (0.47 - 0.92)* 
2.285 (0.93 - 5.60) 
Results are expressed as Hazard Ratio (95 % confidence interval). HC: normalized volume of 
the hippocampus; ERC: normalized volume of the entorhinal cortex; total: sum of the right 
plus left side volumes; AD: conversion of MCI to Alzheimer's disease; CDR: Clinical 
Dementia Rating Scale. 
* p < 0.05 
# p < 0.01 
## p < 0.001 
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6. DISCUSSION 
 
6.1. Study subjects 
 
The MCI and control subjects studied in this work have been collected from two large 
population-based cohorts. This is of importance when interpreting the results from a brain 
MRI study-design that concentrates on MCI, compared to studies where subjects are collected 
from a memory clinic. Noteworthy is also the careful clinical evaluation and diagnosis applied 
in the Kuopio cohorts. The criteria set used for MCI diagnosis (Petersen et al., 1995; Smith et 
al., 1996) represent that most widely used at the time when MCI patients started to be 
collected in our research center. From the two Kuopio cohorts, a database was compiled 
suitable for the objectives and aims of this work, resulting in a large and representative group 
of subjects (n=65 MCIs and n=59 controls), for whom the brain MRI scans were evaluated. 
Thus, this is a relatively large MR imaging study with a well documentated MCI population. 
 
Limitations of such a long-term imaging-study are the changes and updates in scanning 
parameters and protocols. This had implications on the number of subjects included in the 
VBM-based study (n=51 MCIs and n=32 controls). In addition, a further limitation is the 
small number of subjects homozygous for APOE є4 allele, especially when studying the 
differences between and within the groups of stable MCI and progressive MCI (n=3, 
respectively n=5), but this is the case for our study-population in the way the APOE alleles 
are distributed. 
 
6.2. MRI techniques 
 
The ROI-based volumetry is a basic method to investigate atrophy in the brain, though limited 
to the region planned to be studied, and it could be easy to apply also in the clinical work, 
provided that the tracer would have enough experience in performing the task. Nevertheless, 
the time needed to accomplish such a task may still be of inconvenience for a clinical 
purpose. A visual rating method is certainly much quicker, with a time required of 1-2 
minutes per subject (Wahlund et al., 2000), and for that reason it is more convenient for use as 
a routine diagnostic tool in future dementia investigations. The VBM method is a more 
advanced method intended to investigate atrophy taking a global view of the brain, but it is 
not possible to apply it as a diagnostic tool in routine clinical work. However, VBM method is 
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a very useful research tool. It provides an in vivo insight into morphological changes in the 
brain at the group level, but it requires a set of normative images taken with the same scanner. 
Nevertheless, the purpose of this study was not to determine what would be the best imaging 
method for detecting atrophy in brain during clinical work, but this could be one point for 
future study. 
 
A strong point of this work is that with only ROI-based method this imaging study is an in 
vivo evidence supporting the Braak&Braak statement (Braak and Braak, 1991 a; Braak et al., 
1993), showing that entorhinal atrophy precedes the atrophy in the hippocampus in MCI, 
whereas hippocampal atrophy is more prominent in AD. Additionally, the present imaging 
study could map the atrophy that occurs in the brain during a preclinical AD phase, the MCI 
stage, moreover taking into account the influence of APOE genotype, a well known risk 
factor for AD (Farrer et al., 1997). The novelty of this work, compared to previous research 
done in MCI subjects, is that we examined the effects of the APOE є4 allele on brain 
morphometry in MCI using the VBM method. 
 
Although there are other good predictors for AD, the ERC and hippocampal volumes were the 
only features to predict conversion to AD from the MCI stage, which had been diagnosed 
according to the Mayo Clinic criteria (Petersen et al., 1995; Smith et al., 1996). When using 
VBM, other regions were also shown to be implicated in MCI, but are there other and/or 
better predictors of dementia/AD than the ERC and hippocampal volumes, it is not shown in 
this work. This is an objective for a future study for the Kuopio cohorts, when applying for 
that purpose an automatic imaging method to map the entire brain, with VBM or other new 
imaging techniques. If VBM analyses are to be conducted, then newer software than the 
SPM99 (www.fil.ion.ucl.ac.uk/spm) could be used, and that would allow more accurate 
image processing. However, that would make it more difficult to compare the results even 
within the same research group. There are divergences already when trying to compare the 
findings using ROI and VBM (Good et al., 2002, Tisserand et al., 2002 and Karas et al., 
2003). For example, in study I the percentage volume loss in MCI relative to controls was 
greater on the left hippocampus and ERC, while in study II the predominant unilateral 
atrophy was on the right side. This may be accounted for the different amount of subjects 
included in the two studies, study II having a reduced amount of both, MCI and control 
subjects, or for the differences in the applied two MRI techniques to study the brain: manual 
and automatic estimations, or for both of the reasons. The VBM method also entails some 
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limitations and possible confounders that may have importance on the results. For example, 
the quality of the scans given by the reduction of gray/white matter contrast in the diseased 
people and the greater frequency of motion effects in this group may be of importance. 
Moreover, the registration errors of regional specificity that may appear with the spatial 
normalisation, especially of small structures, such as hippocampus or ERC are, may be more 
variable in a diseased group, which might reduce the sensitivity of VBM to detect changes, 
that otherwise would have higher intensity on manual measurements. Another inconvenience 
when trying to compare studies is the statistical p value used for analysis when applying 
VBM, some using p<0.001 value uncorrected, while others have the p corrected for multiple 
comparisons. For a very heterogeneous group such as MCI, a p<0.001 value uncorrected may 
be a better choice, while from the statistical point of view the other method would be 
preferable. Ultimately, the choice depends on the study design. We used p<0.001 uncorrected, 
but we found quite large, anatomically coherent groups of voxels that are significant, 
therefore in statistical terms this design is not a major problem. 
 
6.3. ROI- and VBM-based volumetry 
 
The volumetric studies performed here using both ROI- and VBM- based techniques were 
never intended for determining the comparative value of these two techniques. They are of 
complementary importance, one to determine in vivo the value of ERC atrophy over that of 
hippocampal atrophy in MCI (study I), other to in vivo map the gray matter loss in MCI 
(studies II and III). To the best of our knowledge until study II, there was only one 
published study using VBM in MCI (Chetelat et al., 2002), but this had a slightly smaller 
sample and different operational criteria for MCI. 
 
6.3.1. ROI-based volumetry (study I) 
 
6.3.1.1. ROI-based volumetry in AD vs. controls 
 
An imperative amount of MRI volumetric studies have been dedicated to examining MTL 
atrophy in AD, and our results of significantly reduced ERC and hippocampal volumes in 
patients with AD compared with controls are in consensus with those from the literature. Our 
findings revealed a 36% ERC volume loss in the AD group compared with controls, which is 
in agreement with an earlier study by Juottonen et al. (1998 b) where a 40% reduction of ERC 
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volume was found between the two studied groups. In the study by Laakso et al. (1995), the 
right and left hippocampal volumes decreased by 38% in patients with AD (n=32) compared 
with controls (n=16). Similarly, our findings revealed a 37% total hippocampal volume loss 
and a reduction of 36% in the right and 39% in the left hippocampus, in the AD group 
compared with the controls. While in our study the magnitude of the ERC changes (36%) was 
similar to that of the hippocampal changes (37%) in AD patients, Du et al. reported a more 
intense atrophy in the ERC (39%) than that in the hippocampus (27%) in the AD group (Du et 
al., 2001). However, the variability in measurements of ERC is greater than that of the 
hippocampus, and anatomical ambiguity exists when depicting the ERC boundaries on MRI, 
especially in the AD patients (Juottonen et al., 1999). 
 
6.3.1.2. ROI-based volumetry in AD vs. MCI 
 
While the interest in the MCI group of subjects increased, also the MRI volumetric studies 
that where dedicated to AD brought results from comparisons between the two study groups: 
AD and MCI. In our study, though both regions were significantly atrophied in AD patients 
compared with MCI subjects, significantly greater volume loss in hippocampus (32%) than 
that in ERC (23%) appeared in between the two groups. A study designed similarly to ours, 
although the criteria used for diagnosing the MCI did not exactly overlap wth those proposed 
by the Mayo Clinic, was that conducted by Du and colleagues (2001). Yet, our results are in 
contrast to their findings. They claimed that, in the AD group compared with the MCI group, 
the ERC volume loss (30%) was significantly greater than that of the hippocampus (19%). 
We attribute these discrepancies to the differences in the study populations and to the 
variability in depicting a badly atrophied ERC on the MRI scans. Even so, our results are in 
agreement with the Braak&Braak staging theory (Braak and Braak, 1991 a; Braak et al., 
1993), moreover they are substantiated by the results comparing the MCI and control groups. 
Thus, hippocampal atrophy appears to be more representative than ERC atrophy for AD. 
 
6.3.1.3. ROI-based volumetry in MCI vs. controls 
 
Our findings showing that compared with controls, the volumes of the ERC and hippocampus 
are significantly reduced in individuals with MCI, confirmed those from some earlier studies 
(Convit et al., 1997; Killiany et al., 2000; Xu et al., 2000; Du et al., 2001). In addition, we 
found that the ERC volume loss (16%) was significantly greater than the hippocampal volume 
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loss (8%) in MCI versus controls. This differs from the findings of another cross-sectional 
study (Du et al., 2001), which detected no differences in the magnitude of the volume loss 
between ERC (13%) and hippocampus (11%) in MCI. Our results are of interest, given that 
MCI refers to a transitional stage between the cognitive changes of normal aging and those of 
AD, and may represent a preclinical stage of AD. Therefore, our data is well in line with the 
assumption that the pathology of AD starts in ERC, providing in vivo evidence for the 
Braak&Braak stages (Braak and Braak, 1991 a; Braak et al., 1993). The explanation for the 
relatively modest average ERC volume loss (16%) may be that the MCI subjects were derived 
from a population-based cohort, and not from a group of individuals seeking help for memory 
problems. It should be noted that mildly impaired non-demented subjects form a 
heterogeneous group that includes both stable subjects and subjects who will develop AD 
(Petersen et al., 1995; Petersen et al., 1999; Petersen et al., 2001 a), as well as subjects that 
will possibly revert to normal (Larrieu et al., 2002). 
 
6.3.2. VBM-based volumetry in MCI vs. controls (study II & III) 
 
The findings from this thesis when mapping the gray matter loss in MCI subjects are in 
accordance with the one previously published study (Chetelat et al., 2002), using VBM in 
MCI, but with a slightly smaller sample and different operational criteria for MCI. Their data 
reported bilateral thalamic atrophy and some atrophy in the temporal neocortex. Moreover, we 
found a small area of atrophy in the anterior cingulate cortex. This is of interest because in 
animal models of AD, it is claimed that the entorhinal lesions possibly the initial site of AD 
pathology, lead to hypometabolism of the cingulum (Meguro et al., 1999). In addition, in 
humans, it should be noted that hypoperfusion of the cingulate has been proposed to predict 
conversion from MCI to AD (Huang et al., 2002). 
 
The thalamic involvement noted in our study is also a matter of debate in the literature. While 
some VBM studies on AD have not detected thalamic involvement (Ohnishi et al., 2001; 
Good et al., 2002), there are positive studies as well (Baron et al., 2001; Karas et al., 2003). 
More recently, VBM analyses have found some thalamic involvement also in MCI (Karas et 
al., 2004; Chetelat et al., 2005). Our finding of thalamic involvement in MCI subjects (study 
II), was proved to rather appear in carriers of the APOE є4 allele (study III). In a study of 
cognitively normal subjects with a family history of probable AD, Reiman and colleagues 
concluded that compared to noncarriers, APOE є4 carriers had lower cerebral metabolic rates 
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for glucose (CMRgl) in the thalamus, besides other regions already proved to be affected in 
AD (Reiman et al., 2001). Additionally, it has been proposed that a disconnection mechanism 
from the MTL could lie behind the early thalamic metabolic deficit, which may be 
responsible for the atrophy process (Nestor et al., 2004). Moreover, the pathology of AD has 
been suggested to affect also the thalamus (Braak and Braak, 1991 c), yet this issue, and the 
factors underlying the discrepancy, remain to be resolved in future studies. One possibility 
that is worth mentioning is the bias inherent in the method. As Karas et al. stated the thalamus 
is one of the structures, which "lie geographically in locations which are hard to evaluate with 
computational models" (Karas et al., 2003). 
 
An intence atophy was present in the hippocampus-amygdala region, especially for the 
carriers of the APOE є4 allele in MCI subjects, where amygdala atrophy was affected 
bilaterally. Although according to volumetric studies, the amygdala is not a primary region 
affected in AD, ROI-based MRI studies (Cuénod et al., 1993; Boccardi et al., 2002) and some 
histopathological studies have detected damage in this region in AD, with pathological 
changes occurring mainly in the nuclei that receive or give rise to hippocampal or entorhinal 
projections (Vogt et al., 1990; Scott et al., 1991; Mann, 1992). Nevertheless, when studying 
the results in MCI/AD with the most pronounced atrophy occurring in the amygdala, one 
should be aware of the fact that bias may exist when using VBM, which may be greatly 
affected by the reduced gray/white matter contrast in old diseased subjects and the increased 
motion effects on the images. 
 
6.4. Classification with ROI-based volumetry (study I) 
 
6.4.1. Classification of AD and controls 
 
When classifying AD patients and controls, both the hippocampal and the ERC volumes were 
of statistical significance. Yet, this yielded an overall classification of 90.6%, which was 
similar to the 90.7% classification achieved using hippocampus alone; hence the contribution 
of ERC was negligible. Du et al. (2001) found no significant differences in the power of ERC 
and that of the hippocampus in differentiating patients with AD from controls, but they 
improved the classification (89%) between the two groups when using a combination of both 
regional volumes. For the same purpose, Lehéricy et al. (1994) reached 100% accuracy with 
combined volumes of the hippocampus and amygdala, but using the hippocampus alone they 
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achieved an accuracy of only 89% in the correct classification of 26 subjects. A similar power 
of classification (89%) was reported by Laakso and colleagues when using the hippocampus 
alone to differentiate between 55 AD patients and 42 controls (Laakso et al., 1998). 
 
6.4.2. Classification of AD and MCI 
 
Comparing the groups of AD and MCI, an overall classification of 80.5% was obtained when 
using hippocampus, and adding ERC to the model did not improve the classification. The 
only significant variable that entered into the model in a stepwise discriminant analysis was 
the total hippocampal volume, which yielded a classification of 82.3%. Our findings are 
similar to the results from the study by Dickerson et al. (2001) in classifying non-demented 
subjects and AD patients, but the volumetry protocol used was different from ours and non-
demented subjects overlapped only partially wth the MCI subjects. In the study by Killiany et 
al., the ERC alone gave a better accuracy in discriminating mild AD from "questionables" 
(81%) or from converters (85%) than did the hippocampus alone (75%, respectively 76%) 
(Killiany et al., 2002), though again, their ERC volumetry protocol differed considerably from 
ours. Comparable results were reported by Du and colleagues, presenting the volume of ERC 
with a greater power of discrimination than that of hippocampus (Du et al., 2001). Xu and 
colleagues could identify no differences in the power of ERC and hippocampal volumes in 
classifying the MCI and AD groups (Xu et al., 2000). The differences across structural MRI 
studies could be partially explained by the use of the different volumetric protocols, as well as 
by the criteria used for diagnosing MCI and the method to recruit the subjects. 
 
6.4.3. Classification of MCI and controls 
 
To prove in vivo that MCI is a group distinct from controls adds weight to the value of such a 
volumetric study. When Xu et al. (2000) failed to prove the hypothesis that MRI-derived 
measures of the ERC would be superior to hippocampal measures in classifying controls and 
MCIs, de Leon et al. (2001) stated "the hypothesis that the anatomic sequence of AD affects 
the EC prior to the hippocampus remains to be adequately addressed by MRI". In support of 
this theoretical expectance (de Leon et al., 2001), we showed that the ERC volume, but not 
the hippocampal volume, best discriminated MCI subjects from controls. To our knowledge, 
this had not been demonstrated prior to our study, using the same protocol for ERC 
volumetric measurements (Insausti et al., 1998) applied to MCI subjects as defined by 
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Petersen et al. (Petersen et al., 1995; Petersen et al., 1999). For example, there are earlier 
studies on the same topic, but with different protocols and diagnostic criteria, with results also 
favouring ERC over hippocampus. Accordingly, in the longitudinal study by Dickerson et al., 
the authors showed that ERC volume is better than hippocampal volume at distinguishing 
(69%) non-demented individuals (ND) (n=28) from controls (n=34) (Dickerson et al., 2001). 
However, the protocol they used for the ERC volumetric measurements (Goncharova et al., 
2001) was different from ours and the concepts of ND and MCI overlap only partially. In 
another longitudinal study, Killiany and colleagues showed that only ERC could discriminate 
normals from "questionables" (83% accuracy) and from converters (84% accuracy), while the 
comparable discriminant analysis with the hippocampus in both cases was not significant 
(Killiany et al., 2002). The "questionables" and converters could not be discriminated by any 
of the two measured regions. For the classification of "questionables" a clinical dementia 
rating of 0.5 was considered and not the MCADRC criteria of MCI (Petersen et al., 1995; 
Petersen et al., 1999). Retrospectively shown, only a part of them met the criteria for MCI. 
Additionally the ERC protocol was different from ours: they measured only the midregion of 
the ERC from three slices of 1.5 mm thickness each. 
 
6.5. APOE and patterns of brain atrophy in MCI (study III & IV) 
 
The exact mechanisms by which APOE influences AD are not fully understood. Strong 
associations for APOE genotype with AD were shown to exist, since the APOE allele ε4 is 
the most consistently confirmed genetic risk factor for AD (Farrer et al., 1997). It was 
suggested that AD patients, carriers of APOE ε4 allele have more pronounced 
neuropathological changes, and exhibit more prominent atrophy of the MTL, as well as more 
severe memory loss compared to those AD patients with no ε4 allele (Petersen et al., 1995; 
Alberts, 1996; Lehtovirta et al., 2000; Engelborghs et al., 2003). The genetic asset (the 
presence of APOE є4 allele) is consistent with a theory of greater brain vulnerability in є4 
carriers. Our results (study III) show that the presence of APOE є4 in MCI subjects is 
associated with a greater volume loss in the parahippocampal gyrus, including the ERC, as 
well as in amygdala and in the medial dorsal thalamic nucleus. This is in a way, an 
association in crescendo observed in our MCI cohort, as it increases with the increased 
frequency of є4 allele. In the heterozygous group for the APOE є4 allele, only atrophy of 
parahippocampal gyrus, with ERC included, reached the level of statistical significance. As 
far as we are aware, this effect of the APOE є4 on brain had never been previously evaluated, 
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using VBM-technique in MCI subjects. However, our results are of a preliminary nature, 
considering the small number of carriers studied, especially in the homozygous group. 
Nevertheless, our results, of higher frequency of the APOE є4 allele associated with atrophy 
in the brain regions that overlap with those found to be atrophic in the total MCI group when 
compared to controls, are of interest considering that the APOE є4 allele was shown to be a 
risk factor for conversion to MCI in cognitively healthy aged subjects (DeCarli et al., 2001; 
Tervo et al., 2004). Yet, this is just a speculation, as long as longitudinal imaging study-
results on conversion to MCI in normal elderly subjects are not available now. Our results in 
MCI subjects, while employing the VBM-technique, resemble the dose-dependent effect of 
the APOE є4 allele on the extent of atrophy of the MTL in AD patients, which has been 
detected with ROI-based volumetry and presented significantly increased atrophy from 
noncarriers of APOE є4 allele to homozygous carriers, via heterozygous carriers (Lehtovirta 
et al., 1996; Juottonen et al., 1998 a; Geroldi et al., 1999; Geroldi et al., 2000). 
 
The exact mechanism underlying the associations of APOE є4 allele with the AD process is 
elusive. The APOE є4 allele is considered to shift the age of onset of AD (Corder et al., 
1993), but this was not the case in our study. In the present study (study IV), in the 
progressive MCI group, the groups of APOE did not differ in terms of age. Moreover there 
was no difference at baseline in the MMSE score, or CDR sum of boxes in the progressive 
MCI groups of APOE genotype (progressive carriers versus progressive noncarriers). 
However, the number of converters and accordingly the number of carriers that progressed to 
dementia was low in our study and this could have influenced the results achieved. 
 
Nevertheless, the risk of APOE є4 allele for AD was evident also in our sample of MCI 
subjects, although the APOE genotype was not a significant predictor for conversion. Thus, 
while for the APOE є4 allele noncarriers there were no differences in MTL volumes between 
the progressive and stable MCI groups, for the APOE є4 allele carriers the differences in 
MTL volumes were significant between the two groups (progressive versus stable MCI). 
Moreover, in the progressive MCI group, the carriers of at least one ε4 allele had significantly 
reduced hippocampus compared to noncarriers. 
 
The functions of the APOE in brain are still not fully understood. A greater accumulation of 
histopathological AD hallmarks in APOE є4 carriers has been proposed (see for review 
Cedazo-Minguez and Cowburn, 2001). In addition, in the case of a neuronal damage occurred 
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by different injurious agents, the needed neuronal repair of synaptodentritic connections was 
considered to be modulated by the presence of APOE, where the є4 allele was associated with 
impaired cell repair and synaptic remodeling (Mahley and Rall, 2000). The plastic neuronal 
reorganisation, as evaluated by changes in the length and arborization of dendrites, has been 
shown to be impaired in AD carriers of the APOE є4 allele (Arendt et al., 1997). Thus, a poor 
compensatory mechanism to repair neuronal damage additional to more accumulation of 
different histopathological AD features, might account for the more prominent brain atrophy 
in MCI carriers of APOE є4 allele versus noncarriers, with this being even more apparent in 
the MCI progressive group. 
 
6.6. Prediction of AD in MCI (study IV) 
 
During the follow-up time of ~34 months, 13 subjects (21.7%) converted to dementia, with 
the annual conversion rate being 7.7% emphasizing the heterogeneity of MCI. Larrieu and 
colleagues in their longitudinal study found an annual conversion rate of 8.3%, but more than 
40% of cases reverted to normal during 5 years of follow up (Larrieu et al., 2002). In our 
study, seven (12%) out of 60 MCI subjects who entered the follow-up had undergone an 
improvement of cognition by the last evaluation, indicative of the instability inherent in the 
MCI category as a diagnostic entity. MRI volumetric data in combination with 
neuropsychological data and APOE ε4 allele have shown a significant role in predicting the 
risk of AD (Petersen et al., 1995; Albert, 1996). In the present study, we found that the right 
sided volumes of the hippocampus and ERC and the CDR sum of boxes significantly 
predicted the progression of MCI to dementia. In contrast, the MMSE score, WML burden, or 
APOE genotype were not significant predictors of progression. It is well known that the ERC 
occupies a key position for the communication between the hippocampus and the rest of the 
brain. Accordingly, the degeneration of the neuronal architecture in the ERC destroys a large 
functional hippocampal pathway respectively causing memory impairment and cognitive 
deficits associated with AD (Hyman et al., 1984). Indeed, if the patients who developed non-
AD dementia were excluded from our analysis, the only volumes of hippocampi and ERCs 
predicted the progression to AD. These findings are well in line with data reported by Korf 
and colleagues, showing that the visual assessment of MTL structures on MRI using a 
standardized rating scale is a predictor of dementia in MCI subjects independently of e.g. age, 
gender, education, MMSE, CDR sum of boxes, APOE genotype, and WML burden (Korf et 
al., 2004). 
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It has been proposed that the WML burden is associated with cerebrovascular or vascular 
phenomena (Launer, 2003). Additionally, vascular risk factors have been shown to be 
associated with increased risk for AD and MCI (Kivipelto et al., 2001; Kivipelto et al., 2002; 
Tervo et al., 2004). Moreover, there are suggestions that WMLs could contribute to the 
dementia process by accelerating the cognitive decline in MCI subjects (Wolf et al., 2000). 
Nevertheless, we found no association between WMLs and progression of MCI to dementia 
in this population-based cohort. The extent of the WML burden was relatively modest, which 
may be explained by the criteria of MCI used in this study emphasizing the memory loss. 
However, also other studies have indicated that atrophy of MTL structures is a stronger 
predictor of dementia than the amount of WMLs (Korf et al., 2004). 
 
6.7. Future studies 
 
Studies on brain with different MR techniques are important to be applied in the future on 
even larger database of MCI subjects formed in the limit of possibility to please both, the 
objectives and the technical factors implicated in the study protocols. This is of importance to 
further on map the brain in MCI subjects, to try to predict conversion to dementia/AD and to 
determine what the best techniques to apply for those reasons are, from different points of 
view: grade of technical difficulty, cost level and time consuming. 
 
A large post-mortem study-design including histopathological diagnosis and in vivo imaging 
volumetry measurements, as well as in vivo brain mapping findings would provide reliability 
of neuroimaging results and add differential diagnostic value in what concerns dementia 
investigations with high implications in the treatment of dementia. In the coming years 
visualization of neuropathologiacal features such as beta-amyloid accumulation and even 
earlier events in the the pathogenesis of AD using either PET or MRI will be a great 
challenge. In addition, new techniques such as diffusion tensor imaging and arterial spin 
labelling are worth for further studies. 
 
Neuroimaging should be of an imperative value when used in drug trials to investigate rates 
of atrophy and changes in brain during a specific treatment, with high implications in 
monitoring the prognosis and outcome in MCI cohorts and in AD patients. Rates of brain 
atrophy and ventricular dilatation are of interest in longitudinal studies and useful in drug 
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trials in MCI and AD cohorts. For the evaluation of the brain tissue in clinical trials 
importance should be given to both the global brain rates of atrophy and the MTL rates of 
atrophy, possibly with accent on ERC and hippocampus. 
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7. CONCLUSIONS 
 
In conclusion, the strength of the present study is the large size of the MCI sample derived 
from population-based cohorts. Volumetric MRI analysis of the ERC and hippocampus 
provided in vivo evidence that ERC atrophy precedes hippocampal atrophy in AD. In the MCI 
subjects, involvement of other brain areas in addition to the MTL was also present. The 
novelty of this work, compared to previous research done in MCI subjects, is the examination 
of the effects of the APOE є4 allele on brain morphology in MCI using the VBM method. An 
annual conversion rate of 7.7% from MCI to dementia over a follow-up of 34 months was 
observed. Prediction of conversion to AD was aquired with the atrophy of the MTL. The 
APOE є4 allele, although not a predictor of progression to dementia, does seem to modulate 
neurodegeneration, by increasing brain susceptibility to the effects of the disease. MRI 
volumetry remains a useful tool in identifying the anatomical markers for incipient AD. 
 
In summary: 
 
1). The ERC volume loss was dominant over the hippocampal volume loss in MCI, whereas 
more pronounced hippocampal volume loss appeared in mild AD. 
2). Volumetric measurements of the ERC were more powerful than those of the hippocampus 
in discriminating MCI subjects from controls. 
3). Mapping the GM loss with VBM in MCI, the involvement of other brain areas in addition 
to the MTL was found: left superior parietal lobule, left cingulate gyrus and, notably, the 
thalami bilaterally. 
4). The vast majority of the brain atrophy observed at the group level in MCI appears to be 
due to the small group homozygous for the є4 allele. 
5). Atrophy of the ERC and hippocampus, mostly on the right side, predicted the conversion 
to AD. 
6). The CDR score, WML load or ApoE genotyping provided no additional value over that of 
the MTL atrophy in the prediction of progression of MCI to AD.
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